



Cancer

July–December 1994
Volume 74

*An Interdisciplinary
International Journal of the
American Cancer Society*

Editor-in-Chief Robert V. P. Hutter, MD

Editor Emeritus Jonathan E. Rhoads, MD

Managing Editor Diane Scott-Lichter

Assistant Manager Lyn Beamesderfer

Associate Editors Hervy E. Averette, MD
Paul Calabresi, MD
Albert B. Deisseroth, MD, PhD
Gerald D. Dodd, MD
Harmon J. Eyre, MD

Jay R. Harris, MD
Arthur I. Holleb, MD
B. J. Kennedy, MD
Walter Lawrence, Jr., MD

Curtis J. Mettlin, PhD
Gerald P. Murphy, MD
Gregory H. Reaman, MD
Leslie H. Sobin, MD

**Editorial
Advisory Board**

Members

A. Bernard Ackerman, MD
Charles M. Balch, MD
Luther W. Brady, Jr., MD
David G. Bragg, MD
Blake Cady, MD
Paul P. Carbone, MD
Barrie R. Cassileth, PhD
Isidore Cohn, Jr., MD
Edward M. Copeland III, MD
John M. Daly, MD
Vincent T. DeVita, Jr., MD
Philip J. DiSaia, MD
William L. Donegan, MD
L. Peter Fielding, MB
Edwin R. Fisher, MD
Irvin D. Fleming, MD

Joseph F. Fraumeni, Jr., MD
Harold P. Freeman, MD
Emil J. Freireich, MD
Lawrence Garfinkel, MA
Paul S. Gaynon, MD
Mary K. Gospodarowicz, MD
S. B. Gusberg, MD
I. Craig Henderson, MD
Donald Earl Henson, MD
Reginald C. S. Ho, MD
Jimmie C. Holland, MD
James N. Ingle, MD
Walter B. Jones, MD
Leopold G. Koss, MD
John Laszlo, MD


Edward R. Laws, Jr., MD
LaSalle D. Leffall, Jr., MD
Seymour H. Levitt, MD
John N. Lukens, MD
William M. Murphy, MD
Larry Nathanson, MD
Carlos A. Perez, MD
Juan Rosai, MD
Avery A. Sandberg, MD
Jerry A. Shields, MD
Herman D. Suit, MD
Aleksander Talerma, MD
Teresa J. Vietti, MD
Nicholas J. Vogelzang, MD
David P. Winchester, MD

**Corresponding
Members**

Kunio Aoki, MD-Japan
Fausto Badellino, MD-Italy
Ramez N. Bedwani, MD-Egypt
Arturo Beltran, MD-Mexico
Gianni Bonadonna, MD-Italy
Louis J. Denis, MD-Belgium
Praful B. Desai, MD-India
Sándor Eckhardt, MD-Hungary

Jerzy Einhorn, MD, PhD-Sweden
Roberto A. Estévez, MD-Argentina
Robert Flamant, MD-France
Frans G. Geldenhuys, MD-South Africa
Nigel Gray, MD-Australia
Paul Hermanek, MD-Germany

Antonio Carlos C. Junqueira, MD-Brazil
J. Gordon McVie, MD-United Kingdom
Takashi Sugimura, MD-Japan
Zhao-You Tang, MD-China
Nathan Trainin, MD-Israel
Nikolai N. Trapeznikov, MD-Russia



Subject Index—Volume 74

No. 1, July 1, pp. 1-218
 No. 1, July 1, Supplement, pp. 219-536
 No. 2, July 15, pp. 537-788
 No. 3, August 1, pp. 789-990
 No. 3, August 1, Supplement, pp. 991-1192
 No. 4, August 15, pp. 1193-1406
 No. 4, August 15, Supplement, pp. 1407-1512
 No. 5, September 1, pp. 1513-1654
 No. 6, September 15, pp. 1655-1836

No. 7, October 1, pp. 1837-1992
 No. 7, October 1, Supplement, pp. 1993-2214
 No. 8, October 15, pp. 2215-2396
 No. 9, November 1, pp. 2397-2602
 No. 9, November 1, Supplement, pp. 2603-2744
 No. 10, November 15, pp. 2745-2888
 No. 11, December 1, pp. 2889-3076
 No. 12, December 15, pp. 3077-3282

A

Acetaminophen, colorectal cancer and, 1837 (editorial), 1847, 2885
 Acquired immunodeficiency syndrome
 central nervous system lymphoma in, long survival in, 1990 (letter)
 glial tumors in, 686
 glioma in, 1912
 ACTH, paraganglioma production of, 1634
 Actinic keratosis, *bcl-2* protein in, 1720
 Acute leukemia. *See* Leukemia
 Adrenocorticotrophic hormone, paraganglioma production of, 1634
 Aerodigestive cancer, chemoprevention of, 2719
 African Americans
 in clinical trials, 2687
 elderly, mammography for, 2034, 2042
 prostate cancer in, with obstruction, 1607
 testicular cancer in, 1649 (letter)
 Age. *See also* Children; Elderly
 breast cancer screening and
 benefits of, 228, 231, 296, 311
 compliance and, 329, 2194
 breast cancer survival and, 296
 esophageal cancer survival and, 2425
 microsubstaging variables and, in Wilms' tumor, 1817
 Aging. *See also* Elderly
 biology of, 2092
 AIDS. *See* Acquired immunodeficiency syndrome
 Alcohol
 breast cancer and, 288, 1101
 synchronous and metachronous head and neck cancer and, 1933
 Alkaline phosphatase, in urothelial transitional cell carcinoma, prognosis and, 123
 Allergy, to paclitaxel, with one-hour infusion, 1377
 Alpha-fetoprotein, hepatocellular carcinoma-specific, isoelectric focusing detection of, 25

5-Alpha-reductase, for prostate cancer prevention, 2726
 American Cancer Society
 Breast Cancer Research: Current Issues-Future Directions, Aug. 1 Supplement
 Conference on Behavioral and Psychosocial Research, Aug. 15 Supplement
 National Conference on Breast Cancer, July 1 Supplement
 National Conference on Clinical Trials, 2605
 American Stop Smoking Intervention Study for Cancer Prevention, 2062
 Ampullary cancer, p53 protein in, 1542
 Amsacrine, cytotoxicity of, 2857
 Analgesia
 in home care, for elderly, 2139
 immediate vs. controlled release hydromorphone for, 1808
 Analgesics, nonsteroidal anti-inflammatory, colorectal cancer and, 1837 (editorial), 1847, 2885
 Aneuploidy. *See* DNA content
 Angiogenesis
 in breast cancer, prognosis and, 381
 in lung adenocarcinoma, metastasis and, 2245
 Angiogenic growth factors, in breast cancer, 1021, 1584
 Angioimmunoblastic lymphadenopathy with dysproteinemia, dermal T-cell lymphoma and, 1801
 Angioleiomyoma, primary intracranial pleomorphic, 1915
 Angiomatoid malignant fibrous histiocytoma, chemotherapy for, 962
 Anthracyclines, for breast cancer, 1164
 Antibiotics, intravenous, early discontinuation of, in children with fever and neutropenia, 189
 Antibodies
 Helicobacter pylori monoclonal, in gastric cancer, 1525
 human papillomavirus, in cervical cancer, prognosis and, 2307
 Antiemetics
 metoclopramide as, 3204
 ondansetron vs. granisetron as, 1945
 Antigen(s)
 carcinoembryonic
 in colon cancer, 2908

- estrogen receptors and, breast cancer prognosis and, 1519 (editorial), 1575
- estrogen receptor-related, in meningioma, 679
- Ki-67
- in lung cancer, 2468
 - in meningioma, prognosis and, 3176
- proliferating cell nuclear
- esophageal cancer chemoradiosensitivity and, 1693
 - Ki-67 and, in lung cancer, 2468
- prostate specific. *See* Prostate specific antigen
- squamous cell carcinoma, in cervical squamous cell carcinoma, 2497
- Anxiety, psychotherapy for, 1453
- Argyrophilic nucleolar organizer regions
- in ductal carcinoma in situ of breast, 1739
 - in epithelium adjacent to oral squamous cell carcinoma, 3071 (letter), 3245 (letter)
 - in thymoma, prognosis and, 1568
 - in uterine cancer, 3142
- Arterial embolization, with/without cisplatin, for hepatocellular carcinoma, 2449
- Arterial thrombosis, after chemotherapy, for breast cancer, 2808
- Artificial neural network, for breast cancer risk assessment, 2944
- Asbestos, cardiac synovial sarcoma and, 986 (letter)
- Asparaginase, for acute lymphoblastic leukemia, hyperlipidemia and, 3234
- Aspiration biopsy. *See also* Biopsy
- in breast cancer, 1000
- Aspirin, colorectal cancer and, 1837 (editorial), 1847, 2885
- Astrocytoma
- gangliosides in, 3010
 - low grade supratentorial, management and prognosis in, 3247 (letter)
- Ataxia telangiectasia, low- and high-grade non-Hodgkin's lymphoma in, 1649 (letter)
- Autocrine motility factor receptor, in colorectal cancer, prognosis and, 1855
- Autologous bone marrow transplant. *See* Bone marrow transplant
- Autologous mixed lymphocyte reaction, in peripheral T-cell lymphoma, 2843
- Avidin-biotin complex method, for des-gamma-carboxy-prothrombin, in hepatocellular carcinoma, 2918
- B**
- Barrett's esophagus, high grade dysplasia and early cancer in, management of, 1225
- Basal cell carcinoma, *bcl-2* protein in, 1720
- Basement membrane, in colorectal cancer, 592
- Base of skull chordoma, clinicopathology and treatment of, 2261
- Basic fibroblast growth factor-saporin mitotoxin, anti-B16-F10 melanoma activity of, 848
- B-cell malignancies, after T-cell lymphoma, 164
- bcl-2* protein, in epidermal keratinocyte diseases, 1720
- BCNU, for glioblastoma, cerebral glucose metabolism and, 2836
- Behavioral science. *See also* Psychosocial oncology
- in translational research and cancer control, 1409
- Benign prostatic hyperplasia, prostate cancer after, 2347
- Bile duct cancer, extrahepatic, p53 protein in, 1542
- Biologic aging, cancer and, 2092
- Biopsy
- breast
 - fine needle aspiration, 1000
 - percutaneous large core, 256
 - prostate
 - DNA ploidy analysis for, 2811
 - low-yield, reduction of, 3146
- Biphosphonate, for breast cancer, clinical trials of, 1156
- Blacks. *See* African Americans
- Bladder, carcinoma in situ of, host resistance and, 115
- Bladder cancer
- cisplatin for, enhancement of sensitivity to by *c-myc* antisense oligonucleotide, 2546
 - low grade transitional cell, cytologic diagnosis of, 1621
 - muscle-invasive, preoperative radiotherapy for, 2819
 - recurrent/metastatic, chemotherapy response and prognostic factors in, 123
 - in situ, host resistance and, 115
- Bleomycin
- for intermediate-grade non-Hodgkin's lymphoma, 3029
 - for non-Hodgkin's lymphoma, 2657
- Body weight, breast cancer and, 288, 632, 1090
- Bone marrow metastases, clinicopathology of, 2403
- Bone marrow micrometastases, in prostate cancer, identification of, 2533
- Bone marrow transplant
- for advanced neuroblastoma, 972
 - for breast cancer
 - clinical trials of, 1132, 1135, 1150, 1156
 - with high-dose chemotherapy, 532
 - radiation-induced hematologic toxicity and, 2956
 - reimbursement for, 491
 - for multiple myeloma, with high-dose melphalan, 2930
 - with single-cycle high-dose cyclophosphamide, for relapse, 715
- Bone metastasis, in breast cancer, IV pamidronate for, 2949
- Bone morphogenetic proteins, immunohistochemical detection of, in bone and soft tissue sarcomas, 842
- Bone scan, granulocyte colony stimulating factor-induced changes in, in breast cancer, 1887
- Bone tumors, cytogenetic findings in, 2268
- Bowen disease, *bcl-2* protein in, 1720
- Brachytherapy. *See also* Radiation therapy
- pediatric, 733
- Brain, white matter changes in, with cranial irradiation, 2828
- Brain stem glioma, radiotherapy for, in children, 1827
- Brain stem metastasis, in prostate cancer, 2516
- Brain tumors. *See also specific types*
- thallium imaging of, 3080 (editorial), 3190
- BRCA1 gene, familial breast cancer and, 1013
- Breast biopsy
- fine needle aspiration, 1000
 - percutaneous large core, 256

Breast cancer

- adjuvant therapy for, parametric survival analysis of, 2483
- advanced/metastatic, multidisciplinary management of, 416
- age-related survival in, 301
- alcohol and, 1101
- angiogenic growth factors in, 1021, 1584
- bone marrow transplant for
 - with high-dose chemotherapy, 532
 - reimbursement for, 491
- bone metastasis in, IV pamidronate for, 2949
- carcinoembryonic antigen and estrogen receptors in, prognosis and, 1519 (editorial), 1575
- carcinomatous meningitis and, 3135
- changing patterns of, 1523 (editorial)
- chemotherapy for
 - arterial thrombosis after, 2808
 - candidiasis after, radiologic findings in, 1360
 - with granulocyte colony stimulating factor, 2307
 - legal issues in, 491
 - in locally advanced disease, 453, 466
- clinical trials for, 2606
 - Eastern Cooperative Oncology Group, 1132
 - International Breast Cancer Study Group, 1139
 - National Cancer Institute of Canada, 1150
 - Southwest Oncology Group, 1132
 - in Sweden, 1156
 - United Kingdom Co-ordinating Committee on Cancer Research, 1160
- cytotoxic tumor-infiltrating lymphocytes in, 1275
- diagnosis of, legal issues in, 271, 486, 491
- dietary fat and, 288, 1055, 1078, 1085, 1125
- dietary fiber and, 1125
- ductal in situ
 - argyrophilic nucleolar organizer regions in, 1739
 - biology and management of, 350
 - in male, 1289
 - with nipple discharge, management of, 1294
 - pure vs. mixed with infiltrating cancer, 2964
- early
 - adjuvant chemotherapy for, 401
 - prognostic factors in, 381
- in elderly, 2160
 - chemotherapy for, 2165
 - surgery for, 2160
- estrogen and, 1111, 1125
- estrogen receptors in
 - carcinoembryonic antigen and, prognosis and, 1519 (editorial), 1575
 - changing patterns of, 1523 (editorial)
 - mutations of, hormone resistance and, 1026
 - prognosis and, 864, 1519, 1575
 - rising levels of, 1601
- estrogen replacement after, 512
- etiology of, involution and, 424
- experimental therapies for, reimbursement for, 491
- familial
 - BRCA1 gene and, 1013
 - monitoring for, psychological aspects of, 1184
- fine needle aspiration biopsy in, 1000
- gene therapy for, 1021, 2215 (editorial)
- genetic alterations in, 2281
- genetic epidemiology of, 279
- granulocyte colony stimulating factor for, bone scan changes after, 1887
- growth suppression of, by photoproducts and tamoxifen, 1725
- heterocyclic amines and, 1063, 1070
- hormonal prevention of, clinical trial of, 2726
- incidence and mortality trends in, 222, 995
- infiltrating lobular
 - conservative surgery and radiation therapy for, 640
 - vs. infiltrating ductal, 986 (letter)
- insulin-like growth factor 1 in, tamoxifen effects on, 618
- legal issues in, 271, 486, 491
- locally advanced, management of, 453, 466
- locoregional control of, 1840
- lumpectomy for, 362
 - patient selection for, 363, 366
- lumpectomy in, patient selection for, 430
- male
 - ductal in situ, 1289
 - tamoxifen for, side effects of, 74
- management of, legal issues in, 281, 486, 491
- mastectomy for
 - breast reconstruction after, 376, 436
 - in silicone-intolerant patient, 440
 - medical oncology and, 362
- mesenchymal-epithelial interactions in, 1030
- micrometastases in, reverse-transcriptase polymerase chain reaction for, 1595
- midkines in, 1584
- molecular genetics in treatment of, 2215 (editorial)
- multicentric vs. multifocal, clonal analysis of, 872
- newly diagnosed, physician-patient communication in, 336
- node-negative, DNA ploidy and S-phase cell percentage in, 1752
- node-positive, *c-erbB2* overexpression in, 2991
- nutritional factors in, 288, 1055, 1063, 1071, 1076, 1085, 1125
- percutaneous large core biopsy for, 256
- PhIP and, 1063
- piroxantrone for, 1733
- pleiotrophins in, 1584
- during pregnancy, 518
- pregnancy after, 528
- prevention of, conjugated linoleic acid for, 1050
- quality-of-life assessment in, 410
- radiation therapy for
 - hematologic toxicity of, chemotherapy effect on, 2956
 - in locally advanced disease, 453, 466
 - postmastectomy, 477
 - in recurrent and metastatic disease, 450
- Reach to Recovery program for, 372, 2172
- recurrence of, in transverse rectus abdominis flap, mammographic detection of, 2804
- reproductive history in, prognosis and, 1591

- risk of
 - screening utilization and, 625
 - visceral obesity and, 632
 - risk prediction for, artificial neural network for, 2944
 - screening for. *See also* Mammography
 - age-related compliance with, 329
 - Breast Cancer Detection Demonstration Program for, 296
 - in elderly, 2009, 2028, 2034, 2042, 2046, 2190, 2194
 - epidemiologic factors and, 228
 - in high-risk women, psychological aspects of, 1184
 - interpretation of abnormalities on, 244, 342
 - interventions for increased use of, 323
 - legal issues in, 271, 486, 491
 - National Breast Screening Study of Canada of, 1196, 1207
 - in older black women, 2034, 2042
 - in older Hispanic women, 2028, 2042
 - population-based survival and, 3126
 - psychosocial issues in, 1474
 - quality assurance for, 239
 - state legislation for, 263
 - in socioeconomically disadvantaged, 2042
 - trials of, 1196, 1204, 1207, 1212
 - use of by high vs. low risk women, 625
 - for women aged 40-49, 231, 296, 311
 - secondary prevention of, in high-risk women, 1474
 - S-phase fraction and nuclear size in, prognosis and, 2287
 - stromelysin-3 in, 1045
 - survival in, age and, 301
 - tamoxifen for
 - effect of on lipid peroxide and antioxidative system, 78
 - insulin-like growth factor 1 and, 618
 - side effects of, in males, 748
 - targeted toxins for, 1006
 - urokinase plasminogen activator in, prognosis and, 2276
 - for women aged 40-49, 1196, 1204, 1207, 1212
 - Breast Cancer Detection Demonstration Program, 296
 - age coverage data from, 296
 - survival data from, 301
 - Breast conservation, 362
 - clinical trials of, 2606
 - in collagen vascular disease, 430
 - contraindications to, 362
 - for ductal carcinoma in situ, with intraductal spread, 1294
 - for elderly, 2160
 - for infiltrating lobular cancer, 640
 - in node-negative elderly women, 878
 - patient selection for, 362, 366, 430
 - resection margins in
 - evaluation of, 1660 (editorial)
 - recurrence and, 1746
 - for tumors >3 cm, 1283
 - Breast involution, cancer etiology and, 424
 - Breast-ovary cancer syndrome, risk determination for, 2341
 - Breast reconstruction, 376
 - patient selection for, 436
 - recurrence in transverse rectus abdominis flap after, mammographic detection of, 2804
 - in silicone-intolerant patients, 440
 - surgical options for, 436
 - Bromodeoxyuridine labeling index, MIB-1 and Ki-67 proliferating cell indices and, in glioma, 1921
 - Bronchoalveolar lavage fluid
 - neuron-specific enolase in, 1552
 - nitrites/nitrates and cytokines in, 1546
 - Bronchoscopy, in early-stage lung cancer, 3113
 - Burkitt's leukemia, in HIV-positive patient, 1261
 - Burkitt's lymphoma, CNS therapy in, spinal cord toxicity of, 3034
- C**
- CA-125, in postmenopausal pelvic mass diagnosis, vs. ultrasound and pelvic exam, 1398
 - Calcitonin gene-related peptide, in Maffucci's syndrome, 949
 - 9-aminoCamptothecin, for breast cancer, 1164
 - Canada, breast cancer clinical trials in, 1132, 1150
 - Canadian National Breast Cancer Screening Study, 1196, 1207
 - Cancer
 - early-stage, cancer procoagulant in diagnosis of, 1367
 - in elderly. *See* Elderly
 - in Hispanics, National Cancer Data Base report on, 2386
 - Cancer control
 - behavioral science in, 1409
 - public health strategies for, 1433
 - Cancer diagnosis. *See also* Screening
 - psychosocial issues in, 1458, 1464, 1474
 - Cancer incidence, trends in, in Connecticut 1935-1991, 2863
 - Cancer pain
 - depression and, 2570
 - immediate vs. controlled release hydromorphone for, 1808
 - management of, in home care of elderly, 1239
 - in ovarian cancer, 907
 - Cancer prevention
 - chemotherapeutic, for aerodigestive cancer, 2719
 - clinical trials for, 2625, 2683, 2719, 2726, 2734. *See also* Clinical trials
 - observational evidence and, 2625
 - dietary, clinical trials of, 2734
 - for elderly, government advocacy and action for, 2067
 - health promotion and, 1418
 - hormonal, clinical trials for, 2726
 - Cancer procoagulant, in early-stage cancer diagnosis, 1367
 - Cancer survivors, quality of life of, 1484
 - Cancer treatment, clinical trials for. *See* Clinical trials
 - Candidiasis, chemotherapy-related, radiologic findings in, 1360
 - Carboplatin
 - for breast cancer, clinical trials of, 1156
 - for CNS germinoma, preradiotherapy, 940
 - for lung cancer, with etoposide and radiotherapy, 1243
 - for non-small cell lung cancer, with radiotherapy, 1874
 - for ovarian cancer, with granulocyte macrophage colony stimulating factor, 664
 - y-Carboxylation, vitamin K-dependent, in hepatocellular cancer, 1533

- des- γ -Carboxyprothrombin, in hepatocellular carcinoma, 2918
- Carcinoembryonic antigen
in colon cancer, 2908
estrogen receptors and, breast cancer prognosis and, 1519 (editorial), 1575
- Carcinogenesis, prenatal, 1674
- Carcinoid tumors, interferon-alpha and 5-fluorouracil for, 958
- Carcinomatous meningitis, in breast cancer, 3135
- Cardiac synovial sarcoma, asbestosis and, 986 (letter)
- Cardiotoxicity
of interleukin-2, 3212
with interferon-alpha, 2850
late-doxorubicin, in children, 182
of verapamil, with intrahepatic arterial infusion, 810
- Carbustine, for glioblastoma, cerebral glucose metabolism and, 2836
- Catecholamines, in paraganglioma, 142
- Cathepsin B, in lung cancer, prognosis and, 46
- Cathepsin D, in breast cancer, prognosis and, 381
- CCND1/cyclin D1 oncogene amplification, in head and neck cancer, 152
- CD3+ lymphocytes, p55/p75 interleukin-2 receptor expression by, 2562
- Cell surface glycoprotein gp78, in colorectal cancer, prognosis and, 1855
- Central nervous system lymphoma, clinicopathology of, 1383
- Central nervous system toxicity, of chemotherapy, delirium and, in elderly, 1079
- c-erbB-2
in breast cancer, prognosis and, 381
in uterine papillary serous adenocarcinoma, 1778
- c-erbB2, overexpression of, in node-positive breast cancer, 2991
- Cerebral hemisphere glioma, low grade, extent of resection in, 1784
- Cervical cancer
cytokeratin 10 and 13 in, prognosis and, 2314
DNA hypomethylation in, 893
human papillomavirus antibodies in, prognosis and, 2307
involucrin in, prognosis and, 2314
parathyroid hormone-related protein gene expression in, 83
pelvic side-wall vs. central relapse in, 648
radiation therapy for, ovarian transposition for, 774
squamous cell, squamous cell carcinoma antigen and tumor size in, prognosis and, 2497
thrombocytosis in, prognosis and, 90
- Cervical dysplasia, DNA hypomethylation in, 893
- Cervical intraepithelial neoplasia, human papilloma virus-related, vascular adhesion molecules in, 884
- Chemoembolization
for colorectal carcinoma, 1706
transcatheter oily, for hepatocellular carcinoma, 16
- Chemoprevention, of aerodigestive cancer, 2719
- Chemotherapy. *See also specific agents*
for acute myeloid leukemia, 52
for anaplastic thyroid cancer, 1348
for angiomatoid malignant fibrous histiocytoma, 962
for bladder cancer, 123
for breast cancer
adjuvant, 401
in advanced/metastatic disease, 416
arterial thrombosis after, 2808
with bone marrow transplant, 532
candidiasis after, radiologic findings in, 1360
clinical trials of, 1132, 1135, 1139, 1150, 1156, 1160, 2606
with conservative surgery, for tumors 3 cm, 1283
dose intensity and dose response in, 1177
in elderly, 2165
with granulocyte colony stimulating factor, 2307
bone scan changes after, 1887
legal issues in, 491
in locally advanced disease, 453, 466
for locoregional control, 1840
new agents in, 1164
radiation-induced hematologic toxicity and, 2956
for Burkitt's leukemia, in HIV-positive patient, 1261
for carcinomatous meningitis, in breast cancer, 3135
clinical trials for. *See* Clinical trials
for colorectal cancer
in elderly, 2151
intraperitoneal, 2224
in elderly, 2107
delirium and, 2079
for esophageal cancer, 1680
with radiotherapy, 1217
response to, epidermal growth factor receptor and proliferating cell nuclear antigen and, 1693
gastrointestinal emergencies in, indications for surgery for, in children, 203
for glottic cancer, 2781
for Hodgkin's disease, 159
for intermediate-grade non-Hodgkin's lymphoma, 3029
intraperitoneal, with granulocyte macrophage colony stimulating factor, for ovarian cancer, 664
lactose intolerance and, 1627
for lung cancer, with radiotherapy, 1243
for lymphoma of head and neck, 703
for melanoma, preoperative, 2476
for metastatic neuroendocrine anaplastic small cell tumor, in multiple endocrine neoplasia type 1, 2374
for multiple myeloma, 2930
for myxoid liposarcoma, 1265
nausea and vomiting in, ondansetron vs. granisetron for, 1945
for non-Hodgkin's lymphoma, clinical trials of, 2657
for ovarian cancer, with cytoreductive surgery, 656
for retinoblastoma with orbital involvement, 722
spinal cord toxicity of, 3034
for suprasellar germinomas, aqueous vasopressin for diabetes insipidus in, 2589
toxicity of, glutamine TPN supplementation for, 2879
for urothelial transitional cell carcinoma, 123
- Chernobyl nuclear accident, pediatric thyroid cancer incidence after, 748

- Children. *See also particular cancers of childhood*
 adjustment of to cancer, 1496
 brachytherapy for, 733
 brain stem glioma in, radiotherapy for, 1827
 colorectal cancer in, 5-fluorouracil/leucovorin for, 2593
 electron beam intraoperative radiation therapy for, 740
 fever and neutropenia in, early discharge for, 189
 late doxorubicin cardiotoxicity in, 182
 recurrent T-lymphoblastic disease in, interferon alpha-2B for, in children, 197
 sarcomas in, classification of, 2579
 solid tumors in
 clinical trials for, 2710
 5-fluorouracil/leucovorin for, 2593
 thyroid cancer in, after Chernobyl disaster, 748
- Chinese
 chronic lymphoproliferative disorders in, 174
 esophageal cancer in
 p53 protein in, 3089
 squamous esophageal histology and, 1686
 young adult, esophageal cancer morphology in, 573
- Chondrosarcoma, cytogenetics of, 2268
- Chordoma, of base of skull, clinicopathology and treatment of, 2261
- Chromogranin, in prostate cancer, prognosis and, 1899
- Chronic leukemia. *See* Leukemia
- Chronic lymphoproliferative disorders, in Chinese, 174
- Cigarette smoking
 cessation strategies for, for elderly, 2051, 2055, 2062
 histology-based lung cancer incidence and, 1556
 public health strategies for, 1423
 synchronous and metachronous head and neck cancer and, 1933
- Circumcision, penile intraepithelial neoplasia and, 1762
- Cirrhosis, hepatocellular carcinoma and
 concurrent hepatitis B and C virus infection and, 2234, 2442
 hepatitis C virus infection and, 2234, 2442
 in Japan, 2234
- Cisplatin
 for bladder cancer, enhancement of sensitivity to by c-myc antisense oligonucleotide, 2546
 for esophageal cancer, 1680
 with radiotherapy, 1217
 for gastric cancer, glutathione S-transferase-pi and, 1230
 for glottic cancer, 2781
 for head and neck cancer, for radiation sensitization, 1927
 hemolytic-uremic syndrome and, 3059
 for hepatocellular carcinoma, with transcatheter arterial embolization, 2449
 for melanoma, preoperative, 2476
 for non-small cell lung cancer, with radiotherapy, 1874
 for ovarian cancer, with cytoreductive surgery, 656
 for retinoblastoma with orbital involvement, 722
- Cladribine, for solid tumors, 168
- Clark, R. Lee, 1513 (obituary)
- Clinical trials. *See also specific therapeutic modalities*
 American Cancer Society National Conference on, 2605
 behavioral aspects of, 2676
 on breast cancer, 1132, 1135, 1139, 1150, 1156, 1160, 2606
 in cancer prevention, 2625, 2683
 community-based, 2694
 for dietary prevention, 2734
 future direction of, 2739
 of gene transfer therapy, 2739
 for hormonal prevention, 2726
 long-range effects of on quality of life, 2620
 participation in
 barriers to, 2666, 2672, 2676, 2692
 financial, 2662
 patient-related, 2666, 2692
 physician-related, 2672, 2692
 by elderly, 2208
 by minorities, 2687
 for pediatric solid tumors, 2710
 Phase I, prognostic factors in, 1965
 quality assurance in
 for multicenter data monitoring, management, and analysis, 2647
 pathological, 2638
 surgical, 2630
 randomized, 2610, 2614
 ethical issues in, 2653
 reimbursement for, 2662
 Veterans Administration, 2701
- c-myc antisense oligonucleotide, for enhanced sensitivity to cisplatin, in bladder cancer, 2546
- Cognitive deficits, in medulloblastoma/posterior fossa primitive neuroectodermal tumors, perioperative factors in, 965
- Collagen vascular disease, breast conservation surgery in, 430
- Colon cancer. *See* Colorectal cancer
- Color Doppler ultrasonound, for gestational trophoblastic disease, 2361
- Colorectal cancer
 autocrine motility factor receptor in, recurrence risk and, 1855
 basement membrane in, 592
 carcinoembryonic antigen in, 2908
 chemoembolization for, 1706
 in elderly
 chemotherapy for, 2151
 radiation therapy for, 2154
 surgery for, 2147
 embolization for, 1706
 helix pomatia agglutinin in, 3104
 intraperitoneal floxuridine and leucovorin for, 2224
 multidrug resistance in, intrahepatic verapamil for, 2757
 N-acetylation polymorphism in, 3108
 National Cancer Data Base report on, 1979
 nonpolypoid, in familial adenomatous polyposis/Gardner's syndrome, 12
 nonsteroidal antiinflammatory drugs and, 1837 (editorial), 1847
 pediatric, 5-fluorouracil/leucovorin for, 2593
 P-glycoprotein in, 2908
 primary linitis plastica carcinoma, clinicopathology of, 1863
 screening for, 2023
 small flat, clinicopathology of, 2430

- Community Clinical Oncology Program, 2694
- Comorbidity, in elderly
 early cancer diagnosis and, 2101
 treatment decisions and, 2107
- Computed tomography
 in Ewing sarcoma, prognosis and, 988 (letter)
 single photon emission, for brain tumors, 3080 (editorial)
- Confusion, in elderly, 2079
- Congenital melanocytic nevi, DNA content in, 2935
- Conjugated linoleic acid, in breast cancer prevention, 1050
- Cranial radiation, for glioma, white matter changes in, 2828
- Cryosurgery, for giant cell tumors of sacrum, 1253
- Cyclophosphamide
 for angiomatoid malignant fibrous histiocytoma, 962
 for breast cancer
 arterial thrombosis after, 2808
 clinical trials of, 1132, 1135, 1139, 1150, 1156
 with granulocyte colony stimulating factor, 2307
 for Burkitt's leukemia, in HIV-positive patient, 1261
 for intermediate-grade non-Hodgkin's lymphoma, 3029
 for metastatic neuroendocrine anaplastic small cell tumor,
 in multiple endocrine neoplasia type 1, 2374
 for non-Hodgkin's lymphoma, 2657
 dose escalation of, 1939
 for ovarian cancer, with cytoreductive surgery, 656
 for retinoblastoma with orbital involvement, 722
 single-cycle high-dose, with myeloablative therapy and au-
 tologous stem cell transplantation, for relapse, 715
- Cyclosporine, for small cell lung cancer, effects of on doxor-
 ubicin, 834
- Cystectomy, radical, radiotherapy prior to, 2819
- Cytarabine
 for acute myeloid leukemia, 52
 for non-Hodgkin's lymphoma, 2657
- Cytokeratin 10 and 13, in cervical cancer, prognosis and, 2314
- Cytokines
 abnormalities of, in peripheral T-cell lymphoma, 2843
 in bronchoalveolar lavage fluid, in lung cancer, 1546
- Cytometry. *See* Flow cytometry
- Cytoreductive surgery, for advanced ovarian cancer, 656
- Cytosine arabinoside
 for Burkitt's leukemia, in HIV-positive patient, 1261
 pulmonary insufficiency and, 1953
 spinal cord toxicity of, 3034
- D**
- Dacarbazine
 for melanoma, preoperative, 2476
 for myxoid liposarcoma, 1265
- Dactinomycin, for angiomatoid malignant fibrous histiocy-
 toma, 962
- Data falsification, in National Surgical Adjuvant Breast and
 Bowel Project, 780 (letter)
- Daunorubicin
 for acute myeloid leukemia, 52
 cytotoxicity of, 2857
- Dearterialization, liver tumor blood flow and, 2454
- Delirium, in elderly, 2079
- Delta-T lymphocytosis, in thymoma, 2924
- Depression
 effects of age, gender, symptoms, and treatment on, 2128
 pain and, 2570
 psychotherapy for, 1453
- Dermal T-cell lymphoma, angioimmunoblastic lymphade-
 nopathy with dysproteinemia and, 1801
- Dermatofibroma, histology of, 3072 (letter), 66
- Des-gamma-carboxyprothrombin, in hepatocellular carci-
 noma, 2918
- Desmoid tumors, in familial adenomatous polyposis, 1270
- Des-y-carboxy prothrombin, in hepatocellular carcinoma,
 1533
- Diabetes insipidus, aqueous vasopressin for, during chemo-
 therapy, 2589
- Diagnosis. *See also* Screening
 psychosocial issues in, 1458, 1464, 1474
- Diet
 breast cancer and, 288, 1055, 1063, 1071, 1076, 1085, 1125
 in cancer prevention, clinical trials for, 2734
- DNA content
 in breast cancer, 381
 in node-negative disease, 381
 in colon cancer, 2908
 in congenital melanocytic nevi, 2935
 in esophageal cancer, 578
 in gliomas, 920
 in hepatocellular carcinoma, 599
 diagnostic and prognostic utility of, 1713
 in lung cancer, 2468
 in neuroblastoma with opsomyoclonus syndrome, 1821
 in ovarian cancer, 2509
 in ovarian mucinous tumors, 2329
 in prostate cancer needle biopsy tissue, 2811
 in rhabdomyosarcoma, 3227
 in uterine papillary serous adenocarcinoma, 1778
- DNA hypomethylation, in cervical dysplasia/cancer, 893
- Docetaxel, for breast cancer, 1164
- Doxorubicin
 for anaplastic thyroid cancer, 1348
 for angiomatoid malignant fibrous histiocytoma. 962
 for breast cancer
 arterial thrombosis after, 2808
 clinical trials of, 1132, 1150
 cyclosporine effects on, in small cell lung cancer, 834
 cytotoxicity of, 2857
 effects of hepatic artery infusion of verapamil on, 810
 for Hodgkin's disease, 159
 late cardiotoxicity of, in children, 182
 for metastatic neuroendocrine anaplastic small cell tumor,
 in multiple endocrine neoplasia type 1, 2374
 for myxoid liposarcoma, 1265
 for non-Hodgkin's lymphoma, 3029, 2657
 for ovarian cancer, with cytoreductive surgery, 656
 resistance to, intrahepatic verapamil for, 2757
 for retinoblastoma with orbital involvement, 722
- Drug resistance, to topoisomerase II inhibitors, 2857
- Dysplastic nevi, as familial melanoma risk factor, 3118

E

- Eastern Cooperative Oncology Group Breast Cancer Committee, current trials and future directions of, 1132
- 10-EDAM, for breast cancer, clinical trials of, 1135
- Edatrexate, for breast cancer, clinical trials of, 1135, 1164
- Elderly
- breast cancer in, 2160
 - breast conservation for, 878
 - chemotherapy for, 2165
 - screening for, 2009, 2028, 2034, 2042, 2046. *See also* Breast cancer, screening for
- cancer in
- biology of aging and, 2092
 - early diagnosis of, comorbidity and, 2101
 - interaction of age, symptoms, and survival status in, 2071
 - myths and biases about, 2004
 - overview of, 1995
 - psychosocial impact of, 2118, 2128
 - third-party support and reimbursement for, 2200, 2204
 - treatment decisions for, 2107
- in clinical trials, 2208
- colorectal cancer in
- radiation therapy for, 2154
 - surgery for, 2147
- delirium in, 2079
- Hispanic, mammography in, 2028, 2042
- Mediterranean Kaposi's sarcoma in, etoposide vs. vinblastine for, 2783
- prostate cancer in
- conservative treatment of, 2176
 - radiation therapy for, 2174, 2178
- screening in
- for breast cancer, 2009, 2028, 2034, 2042, 2046
 - for colorectal cancer, 2023
 - overcoming barriers to, 2190, 2194
 - for prostate cancer, 2016. *See also* Prostate specific antigen
- smoking cessation by, 2051, 2055, 2062
- targeting information to, 2194
- Electron beam intraoperative radiation therapy, pediatric, 740
- Embolization
- for colorectal carcinoma, 1706
 - transcatheter arterial, with/without cisplatin, for hepatocellular carcinoma, 2449
- Endometrial cancer
- breast cancer and, 279
 - gonadotropin-releasing hormone receptor in, 2555
 - local recurrence of, prognosis and treatment of, 1303
 - nodal metastasis in, risk assessment for, 2502
- Endometrial hyperplasia, medroxyprogesterone for, hormone receptor down-regulation after, 2321
- Enkephalin
- methionine, in Maffucci's syndrome, 949
 - in paraganglioma, 142
- Enucleation, for uveal melanoma, 3073 (letter)
- Epidermal growth factor, dependence of epidermal growth factor receptor expressing ovarian cancer on, 2979
- Epidermal growth factor receptor
- in breast cancer, prognosis and, 381
 - in esophageal cancer
 - chemoradiosensitivity and, 1693
 - clinicopathology and, 795
- Epidermal keratinocytic diseases, *bcl-2* protein in, 1720
- Epidoxorubicin, for breast cancer, with granulocyte colony stimulating factor, 2307
- Epipodophyllotoxins, for retinoblastoma with orbital involvement, 722
- Epirubicin
- for breast cancer, clinical trials of, 1135, 1156
 - cytotoxicity of, 2857
 - for non-small cell lung cancer, with radiotherapy, 1874
- Epstein-Barr virus BZLF-1 replication activator (ZEBRA), IgA antibody against, in nasopharyngeal cancer, prognosis and, 2414
- Epstein-Barr virus infection
- gastric remnant cancer and, 805
 - immunoproliferative small intestinal disease and, 1699
 - nasopharyngeal cancer and, 2397 (editorial)
 - posttransplantation lymphoproliferative disease and, 1959
 - after liver transplant, 2436
- ER.R2, in breast cancer, prognosis and, 864
- Esophageal cancer
- in Barrett's esophagus, management of, 1225
 - chemoradiotherapy for, 1217
 - epidermal growth factor receptor in, 795
 - long-term survival in, 217 (letter)
 - p53 protein in, 3089
 - squamous cell
 - chemoradiation and surgery for, 1680
 - chemoradiosensitivity of, epidermal growth factor receptor and proliferating cell nuclear antigen and, 1693
 - DNA content of, 578
 - lymphocyte infiltration in, human leukocyte antigen-DR and, 586
 - morphology of, in Chinese young adults, 573
 - p53 protein in, 2218
 - with squamous epithelial dysplasia, 2889
 - squamous esophageal histology and, 1686
 - survival in, age and sex and, 2425
 - thoracic, patterns of lymphatic spread in, 4
- Esophagus, Barrett's, high grade dysplasia and early cancer in, management of, 1225
- Estradiol, familial ovarian cancer and, 1318
- Estramustine phosphate, preoperative, for prostate cancer, 3164
- Estrogen
- breast cancer and, 1111
 - dietary factors in, 1125
 - serum levels of, dietary fat and fiber and, 1125
- Estrogen receptor-related antigen, in meningioma, 679
- Estrogen receptors
- in breast cancer
 - carcinoembryonic antigen and, 1519 (editorial), 1575
 - changing patterns of, 1523 (editorial)
 - mutations of, hormone resistance and, 1026
 - prognosis and, 864, 1519, 1575
 - rising levels of, 1601

- in endometrial hyperplasia, impaired down-regulation of, after medroxyprogesterone, 2321
- in meningioma, 679
- Estrogen replacement therapy, in breast cancer patients, 512
- Ethical issues, in randomized clinical trials, 2653
- Ethnic groups. *See also specific groups*
 - in clinical trials, 2687
- Etoposide
 - cytotoxicity of, 2857
 - for esophageal cancer, 1680
 - for Hodgkin's disease, 152
 - for lung cancer, with carboplatin and radiotherapy, 1243
 - for Mediterranean Kaposi's sarcoma, in elderly, 2783
 - for metastatic neuroendocrine anaplastic small cell tumor, in multiple endocrine neoplasia type 1, 2374
 - for non-Hodgkin's lymphoma, 2657
 - for non-small cell lung cancer, with radiotherapy, 1874
 - oral, for prostate cancer, 100
 - for ovarian cancer, intraperitoneal, with granulocyte macrophage colony stimulating factor, 664
- Ewing sarcoma, radiographic and computed tomographic features of, prognosis and, 988 (letter)
- Extrahepatic bile duct/ampullary cancer, p53 protein in, 1542
- Extramedullary plasmacytoma, posttransplantation, 1959

F

- Familial adenomatous polyposis
 - desmoid tumors in, 1270
 - nonpolypoid rectal cancer in, early detection of, 12
- Familial breast cancer, BRCA1 gene and, 1013
- Familial melanoma, dysplastic nevi as risk factor for, 3118
- Familial ovarian cancer
 - follicular phase hormone levels and, 1318
 - galactose metabolism and, 1309, 1318
 - prophylactic oophorectomy for, 545
 - risk determination for, 545, 2341
- Family caregivers, effects of interaction of age, symptoms, and survival status on, 2071
- Fat, dietary
 - breast cancer and, 288, 1055, 1078, 1085, 1125
 - reduction of, clinical trials of, 2734
- FDG scanning, for head and neck cancer, 1193 (editorial)
- Fetus, carcinogenesis in, 1674
- Fever, in children, early discharge for, 189
- Fiber, dietary, breast cancer and, 1125
- Fibroblast growth factor-saporin mitotoxin, anti-B16-F10 melanoma activity of, 848
- Finasteride, for prostate cancer prevention, 2726
- Fine needle aspiration biopsy. *See also Biopsy*
 - in breast cancer, 1000
- Flap, transverse rectus abdominis, cancer recurrence in, mammographic detection of, 2804
- Flow cytometry. *See also DNA content*
 - in breast cancer, aspiration biopsy sample for, 1000
 - for DNA ploidy analysis, vs. image analysis, 3227
 - in hepatocellular carcinoma, 599, 1713
- Floxuridine, intraperitoneal, for colon cancer, 2224
- 18F-2Fluoro-2-deoxyglucose positron emission tomography, for head and neck cancer, 1193 (editorial)

5-Fluorouracil

- for breast cancer
 - arterial thrombosis after, 2808
 - clinical trials of, 1132, 1135, 1139, 1150, 1156
 - with granulocyte colony stimulating factor, 2307
- for carcinoid and islet cell tumors, with interferon-alpha, 959
- for colorectal cancer
 - in chemoembolization, 1706
 - in children, 2593
 - with intraperitoneal chemotherapy, 2224
- for esophageal cancer, 1680
 - with radiotherapy, 1217
- for glottic cancer, 2781
- ocular toxicity of, ice packs for, 945
- for pancreatic adenocarcinoma, 1869
- for renal cell carcinoma, 916
- Flutamide, preoperative, for prostate cancer, 3164
- Folate, prenatal, medulloblastoma incidence and, 3240
- Follicle-stimulating hormone, familial ovarian cancer and, 1318
- Follicular phase hormone levels, familial ovarian cancer and, 1318

G

- Galactose metabolism, in familial ovarian cancer, 1309, 1318
- Gallbladder cancer, p53 protein in, 1542
- Gangliosides, in astrocytoma and primitive neuroectodermal tumors, 3010
- Gardner's syndrome, nonpolypoid rectal cancer in, early detection of, 12
- Gastric adenoma, with malignant transformation, long-term follow-up of, 2896
- Gastric cancer
 - from gastric adenoma, long-term follow-up of, 2896
 - glutathione S-transferase-pi in, cisplatin sensitivity and, 1230
 - H. pylori* monoclonal antibodies in, 1525
 - intestinal metaplasia and, 556
 - preoperative intratumoral OK-432 for, 3097
 - soluble interleukin-2 receptor in, 2745
- Gastric remnant cancer, Epstein-Barr virus and, 805
- Gastrointestinal emergencies, surgical indications in, in children undergoing chemotherapy, 203
- Gene therapy, for breast cancer, 1021, 2215 (editorial)
- Gene transfer therapy, clinical trials of, 2739
- Germ cell tumors. *See also Ovarian cancer; Testicular cancer*
- Germinoma
 - central nervous system, preradiotherapy carboplatin for, 940
 - suprasellar, chemotherapy for, aqueous vasopressin for diabetes insipidus in, 2589
- Gestational trophoblastic disease, color Doppler ultrasonography of, 2361
- Giant cell tumors, of sacrum, cryosurgery for, 1253
- Glial tumors, in acquired immunodeficiency syndrome, 686
- Glioblastoma, carmustine for, cerebral glucose metabolism and, 2836

Glioma

- in acquired immunodeficiency syndrome, 1912
- brain stem, radiotherapy for, in children, 1827
- bromodeoxyuridine labeling index and MIB-1 and Ki-67 proliferating cell indices in, 1921
- low grade cerebral hemisphere, extent of resection in, 1784
- prognostic factors in, 920
- radiotherapy for, white matter changes in, 2828
- recurrent, stereotactic radiosurgery for, 1342
- thallium imaging of, 3080 (editorial), 3190
- Glottic cancer, cisplatin-5-fluorouracil and supracricoid partial laryngectomy for, 2781
- Glutamine supplementation, for drug toxicity, 2879
- Glutathione S-transferase-pi, in gastric cancer, cisplatin sensitivity and, 1230
- Gonadotropin-releasing hormone receptor, in gynecologic tumors, 2555
- gp78, in colorectal cancer, prognosis and, 1855
- Granisetron, vs. ondansetron, for antiemesis, 1945
- Granulocyte colony stimulating factor
 - for breast cancer
 - bone scan changes after, 1887
 - clinical trials of, 1135
 - peripheral blood progenitor cell release and, 2307
 - for cyclophosphamide dose escalation, in non-Hodgkin's lymphoma, 1939
- Granulocyte macrophage colony stimulating factor
 - with intraperitoneal chemotherapy, for ovarian cancer, 664
 - with single-cycle high-dose cyclophosphamide, for relapse, 715
- Great Britain, breast cancer clinical trials in, 1160
- Group therapy, for cancer patients, 1453
- Growth factors, in breast cancer, 1021, 1584
- Gynecologic tumors. *See also specific types and sites*
gonadotropin-releasing hormone receptor in, 2555

H

- Hamartoma, mesenchymal, of liver, 1237
- Head and neck cancer
 - chemoprevention of, 2719
 - positron emission tomography for, 1193
 - before and after radiotherapy, 1355
- PRAD-1 (CCND1)/cyclin D1 oncogene amplification in, 152
- radiation therapy for, cisplatin sensitization for, 1927
- synchronous and metachronous, 1933
- Head and neck lymphoma, treatment of, 703
- Head and neck sarcoma, prognostic factors in, 697
- Health insurance. *See also Medicare; Reimbursement*
for elderly, 2200, 2204
- Helicobacter pylori* monoclonal antibodies, in gastric cancer, 1525
- Helix pomatia agglutinin, in colorectal cancer, 3104
- Hemangiomas, soft tissue, in Maffucci's syndrome, neuropetides and, 949
- Hematologic toxicity, of radiation therapy, chemotherapy effect on, in breast cancer, 2956
- Hemolytic-uremic syndrome, cisplatin-associated, 3059
- Heparin, subcutaneous, for small cell lung cancer, 38
- Hepatectomy, for hepatocellular carcinoma, prognosis after, 2772
- Hepatic artery-portal vein blood flow, dearterialization and, 2454
- Hepatic cirrhosis, hepatocellular carcinoma and concurrent hepatitis B and C virus infection and, 2234, 2442
- hepatitis C virus infection and, 2234, 2442
- in Japan, 2234
- Hepatic transplantation, lymphoproliferative disease after, 1959, 2436
- Hepatitis B infection, with concurrent HCV infection, hepatocellular carcinoma in cirrhotic patients and, 2442
- Hepatitis C virus infection, hepatocellular carcinoma in cirrhotic patients and, 2234, 2442
- Hepatocellular carcinoma
 - blood flow of, dearterialization and, 2454
 - cell nuclearity in, diagnostic and prognostic utility of, 1713
 - in cirrhotic patients
 - hepatitis C virus infection and, 2234
 - with concurrent HBV infection, 2442
 - in Japan, 2234
 - des- γ -carboxyprothrombin in, 2918
 - DNA ploidy in, 599
 - diagnostic and prognostic utility of, 1713
 - extrahepatic malignancies and, 2765
 - hepatectomy for, prognosis after, 2772
 - microwave coagulation therapy for, 817
 - p53 tumor suppressor gene in, in Hong Kong, 30
 - transcatheter oily chemoembolization for, 16
 - vitamin K-dependent gamma-carboxylation in, 1533
- Hepatocellular carcinoma-specific alpha-fetoprotein, isoelectric focusing detection of, 25
- Hepatoma. *See* Hepatocellular carcinoma
- HER-2 *neu* oncogene, in breast cancer, prognosis and, 381
- Heterocyclic amines, breast cancer and, 1063, 1070
- Hispanics
 - cancer in, National Cancer Data Base report on, 2386
 - in clinical trials, 2687
 - elderly, mammography for, 2028
- Histiocytosis, Langerhans' cell, acute promyelocytic leukemia in, 1650 (letter)
- Hodgkin's disease
 - chemotherapy with field radiation for, 159
 - low- and high-grade ataxia telangiectasia in, 1649 (letter)
 - nodular sclerosis, grading of, 708
 - radiation therapy for
 - advances in, 3198
 - ovarian transposition for, 774
 - treatment advances in, 3198
- Home care
 - effects of interaction of age, symptoms and survival status in, 2071
 - for elderly, 2107
 - pain management in, 2139
 - third-party support and reimbursement for, 2200, 2204
- Hong Kong Chinese, hepatocellular carcinoma in, p53 tumor suppressor gene in, 30
- Hormonal prevention, clinical trials for, 2726

- Hormonal therapy. *See also specific agents*
for breast cancer
in advanced/metastatic disease, 416
clinical trials of, 1132, 1135, 1139, 1150, 1156, 1160
for prostate cancer, preoperative, 3164
Hormone receptors. *See also specific receptors*
in endometrial hyperplasia, impaired down-regulation of,
after medroxyprogesterone, 2321
in meningioma, 679
Hormone resistance, in breast cancer, estrogen receptor muta-
genesis and, 1026
Hormones
follicular phase, familial ovarian cancer and, 1318
steroid, breast cancer and, 1111
Human immunodeficiency virus infection
Burkitt's leukemia in, 1261
glial tumors and, 686
nasopharyngeal lymphoid masses in, 3083
Human leukocyte antigen-DR, in esophageal cancer, lympho-
cyte infiltration and, 586
Human papillomavirus, penile intraepithelial neoplasia and,
1762
Human papillomavirus antibodies, in cervical cancer, progno-
sis and, 2307
Human papilloma virus-related cervical epithelial neoplasia,
vascular adhesion molecules in, 884
Hydromorphone, immediate vs. controlled release, 1808
N-(4-Hydroxyphenyl)retinamide, for breast cancer, 1164
4-Hydroxyphenylretinamide, for breast cancer, clinical trials
of, 1135
Hyperlipidemia, in prednisone-asparaginase-treated acute
lymphoblastic leukemia, 3234
Hypersensitivity, to paclitaxel, with one-hour infusion, 1377

I

- Ice packs, for 5-fluorouracil ocular toxicity, 945
ICI D1694cridine, for breast cancer, 1164
Idarubicin, cytotoxicity of, 2857
Ifosfamide, acute pancreatitis and, 1627
Image analysis, for DNA ploidy analysis, vs. flow cytometry,
3227
Immunoglobulin-G antibody against Epstein-Barr virus
BZLF-1 replication activator (ZEBRA), in nasopharyngeal cancer, prognosis and, 2414
Immunoproliferative small intestinal disease, Epstein-Barr vi-
rus infection and, 1699
Immunotoxins, as anticancer agents, 1006
¹¹¹In-pentetreotide imaging, of metastatic neuroendocrine an-
aplastic small cell tumor, in multiple endocrine neo-
plasia type 1, 2374
Insulin-like growth factor 1, in breast cancer, tamoxifen
effects on, 618
Insurance. *See also Medicare; Reimbursement*
for elderly, 2200, 2204
Intelligence deficits, in medulloblastoma/posterior fossa
primitive neuroectodermal tumors, perioperative
factors in, 965
Intensive care unit use, by Medicare patients, 2366

- Interferon-alpha
cardiotoxicity of, 2850
with 5-fluorouracil, for carcinoid and islet cell tumors, 959
for renal cell carcinoma, 1904
Interferon-alpha-2a, for colorectal cancer, in chemoemboliza-
tion, 1706
Interferon alpha-2B, for recurrent T-lymphoblastic disease, in
children, 197
Interferon-gamma
abnormalities of, in peripheral T-cell lymphoma, 2843
intrapleural, for malignant mesothelioma, 2460
Interleukin-2
abnormalities of, in peripheral T-cell lymphoma, 2843
cardiopulmonary toxicity of, 3212
cardiotoxicity of, 2850
cytolytic T cells and, in breast cancer, 1275
p55/p75 interleukin-2 receptor expression by CD3+ T cells
and natural killers cells and, 2562
for renal cell carcinoma, 1904
Interleukin-2 receptor
in gastric cancer, 2745
in non-Hodgkin lymphoma, treatment failure and, 1792
Interleukin-3, for breast cancer, arterial thrombosis after,
2808
Interleukin-4, abnormalities of, in peripheral T-cell lym-
phoma, 2843
Interleukin-6, paraganglioma production of, 1634
Interleukin-10, in non-Hodgkin lymphoma, treatment failure
and, 1792
International Breast Cancer Study Group, current trials and
future directions of, 1139
International Society for Pediatric Oncology classification, for
childhood sarcomas, 2579
Intracranial pleomorphic angioleiomyoma, 1915
Involucrin, in cervical cancer, prognosis and, 2314
IQ heterocyclic amine, breast cancer and, 1063
Ironitecan, for breast cancer, 1164
Islet cell tumors, interferon-alpha and 5-fluorouracil for, 958
Isoelectric focusing, in detection of hepatocellular carcinoma-
specific alpha-fetoprotein, 25

J

- Japan
hepatocellular carcinoma in, in cirrhotic patient, 2234
neuroblastoma screening in, 3223

K

- Kaposi's sarcoma, Mediterranean, in elderly, etoposide vs.
vinblastine for, 2783
Karyotypes, in bone tumors, 2268
Keratinocytic diseases, *bcl-2* protein in, 1720
Ki-67 antigen
in meningioma, prognosis and, 3176
proliferating cell nuclear antigen and, in lung cancer, 2468
Ki-1-positive anaplastic large cell lymphoma, lymphomatoid
papulosis and, 3051
Ki-67 proliferating cell index, bromodeoxyuridine labeling in-
dex and, in glioma, 1921

L

- Lactose intolerance, chemotherapy-induced, 1627
- Langerhans' cell histiocytosis, acute promyelocytic leukemia in, 1650 (letter)
- Laryngectomy, supracricoid partial, for glottic cancer, 2781
- Lavage fluid, bronchoalveolar
neuron-specific enolase in, 1552
nitrites/nitrates and cytokines in, 1546
- Leiomyosarcoma, presenting as mediastinal soft tissue masses, 2251
- Leucovorin
for breast cancer
arterial thrombosis after, 2808
clinical trials of, 1135
for colon cancer
in children, with 5-fluorouracil, 2593
intraoperative, 2224
- Leukemia
acute lymphoblastic, asparaginase and prednisone for, hyperlipidemia and, 3234
acute myelogenous, cytosine arabinoside for, pulmonary insufficiency and, 1953
acute myeloid, 7+3 remission induction in, 52
acute promyelocytic
extramedullary, 1882
in Langerhans' cell histiocytosis, 1650 (letter)
B-cell, after T-cell lymphoma, 164
Burkitt's, in HIV-positive patient, 1261
chronic lymphocytic, prednimustine with total-body irradiation for, 978
- Leukemic meningitis, in splenic lymphoma with villous lymphocytes, 61
- Levamisole, for colon cancer, with intraoperative chemotherapy, 2224
- Lingual squamous cell carcinoma, grading of, 789
- Linitis plastica carcinoma, colorectal, clinicopathology of, 1863
- Linoleic acid, conjugated, in breast cancer prevention, 1050
- Liposarcoma, myxoid, chemotherapy for, 1265
- Liver, mesenchymal hamartoma of, 1237
- Liver transplant
lymphoproliferative disease after, 1959, 2436
- Liver tumors. *See also* Hepatocellular carcinoma
blood flow of, dearterialization and, 2454
- Logistic regression analysis, for cytologic diagnosis of low-grade transitional cell bladder cancer, 1621
- Losoxantrone, for breast cancer, 1164
- Loss of heterozygosity, in breast cancer, 2281
- Lumpectomy. *See* Breast conservation
- Lung cancer
adenocarcinoma, angiogenesis in, metastasis and, 2245
bronchoalveolar lavage fluid in
neuron-specific enolase in, 1546
nitrite/nitrate and cytokine levels in, 1546
cathepsin B in, prognosis and, 46
chemoprevention of, 2719
early-stage, endoscopic criteria of, 3113
histology-based incidence of, time trends in, 1556
non-small cell, neoadjuvant carboplatin and radiotherapy for, 1243
proliferating cell nuclear antigen and Ki-67 in, 2468
screening for, tumor markers in, 1652 (letter)
small cell
doxorubicin for, cyclosporine effects on, 834
subcutaneous heparin for, 38
tumor doubling time in, prognosis and, 2239
- Lung metastases
spontaneous regression of, in osteosarcoma, 2798
surgery for, late survival after, 2791
- Luteinizing hormone, familial ovarian cancer and, 1318
- Lymphadenectomy, retroperitoneal, for nonseminomatous germ cell tumors, 1329
- Lymphadenopathy, angioablastic, with dysproteinemia, dermal T-cell lymphoma and, 1801
- Lymph node metastasis
in endometrial cancer, risk assessment for, 2502
in esophageal cancer, 4
in squamous cell vulvar cancer, 2491
- Lymphocytes
CD3+, p55/p75 interleukin-2 receptor expression by, 2562
tumor-infiltrating cytolytic, in breast cancer, 1275
- Lymphocytosis, delta-T, in thymoma, 2924
- Lymphoid masses, nasopharyngeal, in HIV infection, 3083
- Lymphoma
aggressive, chemotherapy for, clinical trials of, 2657
Burkitt's, CNS therapy in, spinal cord toxicity of, 3034
central nervous system
in AIDS, long survival in, 1990 (letter)
clinicopathology of, 1383
cyclophosphamide dose escalation for, 1939
dermal T-cell, angioimmunoblastic lymphadenopathy with dysproteinemia and, 1801
of head and neck, treatment of, 703
high-grade, spontaneous complete regression of, 3023
interleukin-2 receptor and interleukin-10 in, treatment failure and, 1792
intermediate-grade, chemotherapy for, 3029
Ki-1-positive anaplastic large cell, lymphomatoid papulosis and, 3051
mantle cell lymphoma, multiple lymphomatous polyposis and, 3042
peripheral T-cell, cytokine abnormalities and autologous mixed lymphocyte reaction in, 2843
prednimustine with total-body irradiation for, 978
splenectomy in, 933
splenic, leukemic meningitis in, 61
T-cell, B-cell malignancy after, 164
- Lymphomatoid papulosis, Ki-1-positive anaplastic large cell lymphoma and, 3051
- Lymphomatous polyposis, 3042
- Lymphoproliferative disorders, chronic, in Chinese, 174

M

- Maffucci's syndrome, neuropeptides and, 949
- Malignant fibrous histiocytoma, angiomatoid, chemotherapy for, 962

- Malignant lymphoma. *See* Lymphoma
- Malignant melanoma. *See* Melanoma
- Malignant mesothelioma, intrapleural interferon-gamma for, 2460
- Malignant mixed mesodermal tumor, of female peritoneum, 854
- Malignant paraganglioma, ACTH and interleukin-6 production by, 1634
- Malpractice, in breast cancer diagnosis and management, risk management for, 271, 486, 491
- Mammary gland, development of, mesenchymal-epithelial interactions in, 1030
- Mammography
- age-related benefits of, 228, 231, 297, 311
 - age-related compliance with, 329, 2190
 - assessment of current studies of, 231
 - benefit of, for women aged 40–49, 1196, 1204, 1207, 1212
 - Breast Cancer Detection Demonstration Program for, 296
 - detection of recurrence in transverse rectus abdominis flap on, 2804
 - in elderly, 2009, 2028, 2034, 2042, 2046, 2190, 2194
 - in high-risk women, psychological aspects of, 1188
 - in high vs. low risk women, 625
 - indications for, epidemiologic factors in, 228
 - interpretation of abnormalities on, 244, 342
 - interventions for increased use of, 323
 - legal issues in, 271, 486, 491
 - National Breast Screening Study of Canada for, 1196, 1207
 - nonpalpable lesions detected on, significance of, 1991 (letter)
 - in older black women, 2034
 - in older Hispanic women, 2028
 - population-based breast cancer survival and, 3126
 - psychosocial issues in, 1474
 - quality assurance for, 239
 - state legislation for, 263
 - in socioeconomically disadvantaged, 2042
 - trials of, 1196, 1204, 1207, 1212
 - in women aged 40–49, 231, 296, 311
- Mantle cell lymphoma, multiple lymphomatous polyposis and, 3042
- Mastectomy
- breast reconstruction after, 376
 - patient selection for, 436
 - recurrence in transverse rectus abdominis flap after, mammographic detection of, 2804
 - in silicone-intolerant patient, 440
 - surgical options for, 436
 - for ductal carcinoma in situ, in males, 1289
 - for elderly, 2160
 - medical oncology and, 362
- MCF-7 breast cancer, growth suppression of, by photoproducts and tamoxifen, 1725
- Meat, heterocyclic amines in, breast cancer and, 1063, 1070
- Mediastinal soft tissue masses, smooth muscle tumors presenting as, 2251
- Medicare. *See also* Reimbursement
- breast cancer experimental therapies and, 491
 - intensive care unit use and, 2366
- Mediterranean Kaposi's sarcoma, in elderly, etoposide vs. vinblastine for, 2783
- Medroxyprogesterone, for endometrial hyperplasia, hormone receptor down-regulation after, 2321
- Medullary thyroid carcinoma, N-myc immunoreactivity in, prognosis and, 134
- Medulloblastoma
- adult, prognostic factors in, 2352
 - in children, declining incidence of, 3240
 - IQ decline in, perioperative factors in, 965
- MelQ heterocyclic amine, breast cancer and, 1063
- Melanocytic nevi, congenital, DNA content in, 2935
- Melanoma
- in congenital melanocytic nevi, DNA content and, 2935
 - familial, dysplastic nevi as risk factor for, 3118
 - fibroblast growth factor-saporin mitotoxin activity against, 848
 - interleukin-2 for
 - cardiopulmonary toxicity of, 3212
 - with interferon-alpha, cardiotoxicity of, 2850 - National Cancer Data Base report on, 782
 - preoperative cisplatin, vinblastine, and dacarbazine for, 2476
 - uveal, management of, 3073 (letter)
- Melphalan
- for breast cancer, clinical trials of, 1135
 - for multiple myeloma, 2930
- Menagril, for breast cancer, clinical trials of, 1135
- Menaquinones, in hepatocellular carcinoma, 1533
- Menarche, age at, breast cancer prognosis and, 1591
- Meningioma
- estrogen receptor-related antigen and progesterone in, 679
 - MIB1 staining index in, prognosis and, 3176
- Meningitis
- carcinomatous, in breast cancer, 3135
 - leukemic, in splenic lymphoma with villous lymphocytes, 61
- Menopause, age at, breast cancer prognosis and, 1591
- Merocyanine 540, in breast cancer growth suppression, 1725
- Merodantoin, in breast cancer growth suppression, 1725
- Mesenchymal-epithelial interactions, in mammary gland/prostate development, 1030
- Mesenchymal hamartoma, of liver, 1237
- Mesothelioma, intrapleural interferon-gamma for, 2460
- Metastasis
- bone, in breast cancer, IV pamidronate for, 2949
 - bone marrow
 - clinicopathology of, 2403
 - in prostate cancer, identification of, 2533 - brain stem, in prostate cancer, 2516
 - in lung cancer, angiogenesis and, 2245
 - nodal
 - in endometrial cancer, risk assessment for, 2502
 - in esophageal cancer, 4
 - in squamous cell vulvar cancer, 2491 - pulmonary
 - spontaneous regression of, in osteosarcoma, 2798
 - surgery for, late survival after, 2791
- Methionine enkephalin, in Maffucci's syndrome, 949

- Methotrexate
for breast cancer, clinical trials of, 1132, 1135, 1139, 1156
for Burkitt's leukemia, in HIV-positive patient, 1261
for non-Hodgkin's lymphoma, 2657
spinal cord toxicity of, 3034
- Metoclopramide, controlled release vs. immediate release, 3204
- MIB-1 index
bromodeoxyuridine labeling index and, in glioma, 1921
in meningioma, prognosis and, 3176
- Microwave coagulation, for hepatocellular carcinoma, 817
- Midkines, in breast cancer, 1584
- Mifepristone, for breast cancer, clinical trials of, 1135
- Mitotoxins, as anticancer agents, 1006
- Mitoxantrone, cytotoxicity of, 2857
- Myeloma, multiple, posttransplantation, 1959
- Molecular genetics, in breast cancer treatment, 1021, 2215 (editorial)
- Monoclonal antibodies, *Helicobacter pylori*, in gastric cancer, 1525
- Mucin-producing pancreatic tumors, cytodiagnosis of, 826
- MUC1 mRNA, in breast cancer micrometastases, reverse transcriptase polymerase chain reaction for, 1595
- Müllerian tumor, of female peritoneum, 854
- Multidrug resistance
intrahepatic verapamil for, 2757
to topoisomerase II inhibitors, 2857
- Multiple endocrine neoplasia type 1 syndrome, metastatic neuroendocrine anaplastic small cell tumor in, 2374
- Multiple endocrine neoplasia type 2B, medullary thyroid cancer in, 928
- Multiple lymphomatous polyposis, 3042
- Multiple myeloma
posttransplantation, 1959
three courses of high-dose chemotherapy for, 2930
- Muscle, smooth, malignant tumors of, presenting as mediastinal soft tissue masses, 2251
- Myeloma. *See* Multiple myeloma
- Myocutaneous flap, transverse rectus abdominis, for breast reconstruction, cancer recurrence in, mammographic detection of, 2804
- Myxoid liposarcoma, chemotherapy for, 1265
- N**
- N-acetylation polymorphism, in colorectal cancer, 3108
- Nasopharyngeal cancer
Epstein-Barr virus and, 2397 (editorial)
IgA antibody against Epstein-Barr virus BZLF-1 replication activator in, prognosis and, 2414
- Nasopharyngeal lymphoid masses, in HIV infection, 3083
- National Breast Screening Study of Canada, 1196, 1207
- National Cancer Data Base, for prostate cancer, 1640
- National Cancer Data Base report
on cancer in Hispanics, 2386
on colorectal cancer, 1979
on melanoma, 782
on staging trends, 1974
- National Cancer Institute classification, for childhood sarcomas, 2579
- National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group, 1150
- National Surgical Adjuvant Breast and Bowel Project, notice of falsified data in, 780 (letter)
- Native Americans, in clinical trials, 2687
- Natural killer cells, p55/p75 interleukin-2 receptor expression by, 2562
- Nausea and vomiting
controlled release vs. immediate release metoclopramide for, 3204
ondansetron vs. granisetron for, 1945
- Needle biopsy. *See also* Biopsy
in breast cancer, 1000
in prostate cancer, DNA ploidy analysis for, 2811
- Negligence. *See* Malpractice; Risk management
- Nephrotoxicity, of suramin, in prostate cancer, 1612
- Neuroblastoma
advanced, bone marrow transplant for, 972
clinical trials for, 2710
opsomyoclonus syndrome and, 1821
screening for, 3223
- Neuroendocrine tumors
interferon-alpha and 5-fluorouracil for, 958
in small cell prostate cancer, 3159
- Neurologic complications, in small cell prostate cancer, 3159
- Neuron-specific enolase
in bronchoalveolar lavage fluid, 1552
in prostate cancer, prognosis and, 1899
- Neuropeptides
in Maffucci's syndrome, 949
in renin-producing paraganglioma, 142
- Neutropenia, in children, early discharge for, 189
- Nevi
congenital melanocytic, DNA content in, 2935
dysplastic, as familial melanoma risk factor, 3118
- Nitrates, in bronchoalveolar lavage fluid, in lung cancer, 1546
- Nitrites, in bronchoalveolar lavage fluid, in lung cancer, 1546
- N-myc gene
in medullary thyroid cancer, prognosis and, 134
in neuroblastoma with opsomyoclonus syndrome, 1821
- Nodal metastasis
in endometrial cancer, risk assessment for, 2502
in esophageal cancer, 4
in squamous cell vulvar cancer, 2491
- Nodular sclerosis Hodgkin's disease, grading of, 708
- Non-Hodgkin's lymphoma. *See* Lymphoma
- Nonsteroidal antiinflammatory drugs, colorectal cancer and, 1837 (editorial), 1847, 2885
- Nuclear size, in breast cancer, prognosis and, 2287
- Nucleolar organizer regions
in ductal carcinoma in situ of breast, 1739
in epithelium adjacent to oral squamous cell carcinoma, 3071 (letter), 3245 (letter)
in thymoma, prognosis and, 1568
in uterine cancer, 3142
- Nutrition
breast cancer and, 288, 1055, 1063, 1071, 1076, 1085, 1125
in cancer prevention, clinical trials for, 2734

total parenteral, glutamine supplementation in, for drug toxicity, 2879

O

- Obesity, breast cancer and, 288, 632, 1090
- Ocular toxicity, 5-fluorouracil, ice packs for, 945
- Odansetron, vs. granisetron, for antiemesis, 1945
- OK-432, preoperative intratumoral injection of, in gastric cancer, 3097
- Oncogenic viruses, perinatal infection with, 1675
- Oncotoxins, as anticancer agents, 1006
- Oophorectomy, prophylactic, 545
- Opsomyoclonus syndrome, neuroblastoma and, 1821
- Oral cancer. *See also* Head and neck cancer
 - mortality trends in, 565
 - squamous cell
 - grading of, 789
 - nucleolar organizer regions in adjacent epithelium in, 3071 (letter), 3245 (letter)
- Orbital involvement, in retinoblastoma, chemotherapy for, 722
- Osteosarcoma
 - bone morphogenetic proteins in, immunohistochemical detection of, 842
 - cytogenetics of, 2268
 - pulmonary metastases in, spontaneous regression of, 2798
- Ovarian ablation, for breast cancer, clinical trials of, 1132, 1135, 1139, 1160
- Ovarian cancer
 - advanced, cytoreductive surgery for, long-term survival after, 656
 - breast cancer and, 279
 - DNA content of, prognosis and, 2509
 - epidermal growth factor-dependent growth of, 2979
 - epithelial
 - cell lines for, 900
 - prognostic factors in, 1323
 - familial
 - follicular phase hormone levels and, 1318
 - galactose metabolism and, 1309, 1318
 - prophylactic oophorectomy for, 545
 - risk determination for, 545, 2341
 - familial risk factors for, 545
 - gonadotropin-releasing hormone receptor in, 2555
 - intraperitoneal chemotherapy for, with granulocyte macrophage colony stimulating factor, 664
 - paclitaxel for, exposure times and dose escalation for, 1891
 - pain in, 907
 - postmenopausal, diagnosis of, pelvic exam vs. ultrasound vs. CA-125 in, 1398
 - prophylactic oophorectomy for, 545
 - recurrent, radiotherapeutic palliation in, 2972
 - transforming growth factor-beta in, 90
- Ovarian hormones, familial ovarian cancer and, 1318
- Ovarian mucinous tumors, clinicopathology and prognosis of, 2329
- Ovaries, lateral vs. medial transposition of, for radiation therapy, 774

P

- Paclitaxel
 - for breast cancer, clinical trials of, 1135, 1164
 - one-hour infusion of, 1377
 - for ovarian cancer, exposure times and dose escalation for, 1891
- Pain
 - depression and, 2570
 - immediate vs. controlled release hydromorphone for, 1808
 - in ovarian cancer, 907
- Pain management, in home care, for elderly, 2139
- Palliative radiation therapy, for ovarian cancer, 2972
- Pamidronate
 - for breast cancer, clinical trials of, 1156
 - intravenous, for bone metastases in breast cancer, 2949
- Pancreatic cancer, N-phosphonylacetyl-L-aspartic acid and 5-fluorouracil for, with radiotherapy, 1869
- Pancreatic tumors, mucin-producing, cytodiagnosis of, 826
- Pancreatitis, acute, ifosfamide and, 1627
- Paraganglioma
 - ACTH and interleukin-6 production by, 1634
 - renin-producing, multiple neuropeptide immunoreactivities in, 142
- Parametric survival analysis, of breast cancer adjuvant therapy, 2483
- Parathyroid hormone-related protein gene expression, in cervical cancer, 83
- Parenteral nutrition, glutamine supplementation in, for drug toxicity, 2879
- Pediatric psychosocial oncology, 1496
- Pelvic mass, postmenopausal, diagnosis of, pelvic exam vs. ultrasound vs. CA-125 in, 1398
- Pelvic radiotherapy, for prostate cancer, side effects of, 2520
- Penclomidine, for breast cancer, 1164
- Penile intraepithelial neoplasia, clinicopathology of, 1762
- Penis, circumcision of, intraepithelial neoplasia and, 1762
- Percutaneous large core breast biopsy, 256
- Peripheral blood progenitor cells, release of, with chemotherapy plus granulocyte colony stimulating factor, in breast cancer, 2307
- Peripheral T-cell lymphoma, cytokine abnormalities and autologous mixed lymphocyte reaction in, 2843
- Peritoneum, female, malignant mixed mesodermal tumor of, 854
- p53 gene
 - mutant, in breast cancer, prognosis and, 381
 - in uterine papillary serous adenocarcinoma, 1778
- P-glycoprotein, in colon cancer, 2908
- Pharyngeal cancer, mortality trends in, 565
- Phase I clinical trials, prognostic factors in, 1965
- Pheochromocytoma, multiple neuropeptide immunoreactivities in, 142
- PhIP heterocyclic amine, breast cancer and, 1063
- N-Phosphonylacetyl-L-aspartic acid, for pancreatic adenocarcinoma, 1869
- Physicians, in clinical trials, 2672
- p55 interleukin-2 receptors, expression of by CD3+ T cells and natural killers cells, 2562

- p75 interleukin-2 receptors, expression of by CD3+ T cells and natural killers cells, 2562
- Piroxantrone, for breast cancer, 1164, 1733
- Pituitary hormones, familial ovarian cancer and, 1318
- Pituitary tumors, loss of heterozygosity at retinoblastoma locus in, 693
- Plasma cell dyscrasias, posttransplantation, 1959, 2436
- Plasmacytoma, extramedullary, posttransplantation, 1959
- Pleiotrophins, in breast cancer, 1584
- Pleomorphic angioleiomyoma, primary intracranial, 1915
- Pleural malignant mesothelioma, intrapleural interferon-gamma for, 2460
- Ploidy. *See* DNA content
- Polymerase chain reaction, in breast cancer
aspiration biopsy sample for, 1000
in differentiation of multicentric and multifocal disease, 872
fine needle aspiration biopsy for, 1000
for micrometastases detection, 1595
- Poor, mammography in, 2042
- Portal vein-hepatic artery blood flow, dearterialization and, 2454
- Positron emission tomography
for head and neck cancer, 1193 (editorial)
before and after radiotherapy, 1355
in identification of chemotherapy responders, in glioblastoma, 2836
- Posterior fossa primitive neuroectodermal tumors, IQ decline in, perioperative factors in, 965
- Posttransplantation lymphoproliferative disease, after liver transplant, 2436
- p53 protein
in esophageal cancer, 3089
in esophageal squamous cell carcinoma, 2218
in gallbladder and bile duct carcinoma, 1542
- PRAD-1/cyclin D1 oncogene amplification, in head and neck cancer, 152
- Prednimustine, for chronic lymphocytic leukemia/non-Hodgkin's lymphoma, 978
- Prednisone, for acute lymphoblastic leukemia, hyperlipidemia and, 3234
- Pregnancy
after breast cancer, 528
breast cancer during, 518
later breast cancer prognosis and, 1591
- Prenatal carcinogenesis, 1674
- Prevention. *See* Cancer prevention
- Primitive neuroectodermal tumors
gangliosides in, 3010
posterior fossa, IQ decline in, perioperative factors in, 965
- Procabazine, for intermediate-grade non-Hodgkin's lymphoma, 3029
- Progesterone
breast cancer and, 1111
in meningioma, 679
- Progesterone receptor, in endometrial hyperplasia, impaired down-regulation of, after medroxyprogesterone, 2321
- Prognostic factors. *See also specific cancers*
in Phase I clinical trials, 1965
- Proliferating cell nuclear antigen
esophageal cancer chemoradiosensitivity and, 1693
Ki-67 and, in lung cancer, 2468
- Prostate
low-yield biopsies of, reduction of, 3146
transurethral resection of, cancer after, 2347
- Prostate cancer
bone marrow micrometastases in, identification of, 2533
brain stem metastasis in, 2516
breast cancer and, 279
conservative treatment of, 2176
hormonal prevention of, clinical trial of, 2726
low-yield biopsies in, reduction of, 3146
in men under 50 years, 1768
mesenchymal-epithelial interactions in, 1030
metastatic, pretreatment of, 2182
National Cancer Data Base Report on, 1640
needle biopsy specimens in, DNA content of, prognosis and, 2811
neuroendocrine differentiation in, tumor progression and, 1899
nuclear shape analysis for, 2996
with obstruction, incidence, racial differences, and prognosis in, 1607
preoperative hormonal therapy for, 3164
prostate specific antigen in. *See* Prostate specific antigen
radiation therapy for, 2174
side effects of, 2520
screening for, 3077, 2017. *See also* Prostate specific antigen
overcoming barriers to, 2190, 2194
small cell, neurologic complications in, 3159
staging of, 1 (editorial)
suramin for, renal toxicity of, 1612
TNM classification for, 104
after transurethral resection for benign prostatic hyperplasia, 2347
Us Too support group for, 2188
watchful waiting in, 2178
- Prostate specific antigen
applications of, 1667
immunoassays for
quality assurance for, 1655 (editorial)
standardization of, 1662
indices for, comparison of, 1516 (editorial), 1615
Prostate specific antigen density, applications of, 2984, 3002, 1516 (editorial), 1615, 1667
- Prostate specific antigen doubling time, in prostate cancer, prognosis and, 670
- Prothrombin, des-gamma-carboxy, in hepatocellular carcinoma, 1533
- Psychosocial effects of cancer
interaction of age, symptoms and survival status and, 2071, 2128
on older vs. younger patients, 2118
- Psychosocial oncology
pediatric, 1496
psychotherapy and, 1453
quality of life and, 1445, 1458
research in, 1458

- screening and, 1464, 1474, 1482
 - symptom control in, 1438
 - in underserved, 1503
- Psychotherapy, for cancer patients, 1453
- p53 tumor suppressor gene, in hepatocellular carcinoma, in Hong Kong, 30
- Public health
- cancer control strategies and, 1433
 - physicians' role in, 1418
 - smoking cessation strategies and, 1423
- Pulmonary insufficiency, cytosine arabinoside-induced, 1953
- Pulmonary metastases
- spontaneous regression of, in osteosarcoma, 2798
 - surgery for, late survival after, 2791
- Pulmonary toxicity, of interleukin-2, 3212
- Pyrazoloacridine, for breast cancer, 1164
- Q**
- Quality assurance
- for clinical trials, for multicenter data monitoring, management, and analysis, 2647
 - in clinical trials
 - for pathology, 2638
 - for surgery, 2630
 - for mammography, 239
 - for prostate specific antigen assays, 1655 (editorial)
 - in radiation oncology, 2642
- Quality of life
- in breast cancer, assessment of, 410
 - in cancer survivors, 1484
 - clinical trials and, 2620
 - in elderly patients, 2107
 - individual and policy implications of, 1445, 1458
- R**
- Race. *See also* African Americans
- prostate cancer with obstructive symptoms and, 1607
 - testicular cancer and, 1649 (letter)
- Racial minorities, in clinical trials, 2687
- Radiation, prenatal carcinogenesis and, 1675
- Radiation exposure, pediatric thyroid cancer after, in Chernobyl, 748
- Radiation therapy. *See also* Brachytherapy
- for anaplastic thyroid cancer, 1348
 - for base of skull chordoma, 2261
 - for bladder cancer, preoperative, 2819
 - for brain stem glioma, in children, 1827
 - for breast cancer
 - clinical trials of, 1132, 1135, 1139, 1150, 1156, 1160
 - in collagen vascular disease, 430
 - with conservative surgery, for tumors >3 cm, 1283
 - hematologic toxicity of, chemotherapy effect on, 2956
 - in infiltrating lobular disease, 640
 - in locally advanced disease, 453, 466
 - for locoregional control, 1840
 - with lumpectomy, 362, 453, 466, 640
 - postmastectomy, 477
 - in recurrent and metastatic disease, 450
 - clinical trials of. *See* Clinical trials
 - for colorectal cancer, in elderly, 2154
 - cranial, white matter changes in, 2828
 - in elderly, 2107
 - electron beam intraoperative, pediatric, 740
 - for endometrial cancer, local recurrence after, 1303
 - for esophageal cancer, 1680
 - with chemotherapy, 1217
 - response to, epidermal growth factor receptor and proliferating cell nuclear antigen and, 1693
 - for head and neck cancer
 - cisplatin sensitization for, 1927
 - positron emission tomography before and after, 1355
 - for Hodgkin's disease, 159
 - advances in, 3198
 - intraoperative, rationale for and results of, 537 (editorial)
 - lateral vs. medial ovarian transposition in, 774
 - for lung cancer, with carboplatin and etoposide, 1243
 - for lymphoma of head and neck, 703
 - for medulloblastoma, survival after, 2352
 - for non-small cell lung cancer, with chemotherapy, 1874
 - for ovarian cancer, for palliation, 2972
 - for pancreatic adenocarcinoma, with chemotherapy, 1869
 - for prostate cancer
 - in elderly, 2174, 2178
 - relapse after, prostate specific antigen doubling time and, 670
 - side effects of, 2520
 - skin changes after, causes of, 3063
 - small intestine protection in, topical WR-2721 for, 2379
 - spinal cord toxicity of, 3034
 - total body, for chronic lymphocytic leukemia/non-Hodgkin's lymphoma, 978
 - transcutaneous oxygen pressure after, 3063
- Radioenteritis, prevention of, topical WR-2721 for, 2379
- Radiography
- chemotherapy-related candidiasis presenting on, in breast cancer, 1360
 - in Ewing sarcoma, prognosis and, 988 (letter)
- Radiosurgery, stereotactic, for recurrent glioma, 1342
- Reach to Recovery, 372, 2172
- Rectal cancer. *See also* Colorectal cancer
- nonpolypoid, in familial adenomatous polyposis/Gardner's syndrome, 12
- Rectus abdominis flap, for breast reconstruction, cancer recurrence in, mammographic detection of, 2804
- Reimbursement
- for breast cancer experimental therapies, 491
 - for care of elderly, 2200, 2204
 - for clinical trials, 2662
- Renal cell carcinoma
- 5-fluorouracil for, 916
 - interferon-alpha for, 1904
 - interleukin-2 for, 1904
 - cardiopulmonary toxicity of, 3212
 - in von Hippel-Lindau disease, conservative surgery for, 2541
- Renal toxicity, of suramin, in prostate cancer, 1612
- Reproductive history, breast cancer prognosis and, 1591

Retinoblastoma, orbital involvement in, chemotherapy for, 722

Retinoblastoma locus, loss of heterozygosity at, in pituitary tumors, 693

all-trans-Retinoic acid, for breast cancer, 1164

Retroperitoneal lymphadenectomy, for nonseminomatous germ cell tumors, 1329

Reverse-transcriptase polymerase chain reaction, for breast cancer micrometastases, 1595

Rhabdomyosarcoma

classification of, 2579

clinical trials for, 2710

DNA content in, 3227

Risk management, for breast cancer diagnosis and management, 271, 486, 491

mRNA

MUC1, in breast cancer micrometastases, reverse transcriptase polymerase chain reaction for, 1595

gamma-carboxylase, in hepatocellular carcinoma, 1533

RU-486, for breast cancer, clinical trials of, 1135

S

Sacrum, giant cell tumors of, cryosurgery for, 1253

Sarcoma

cardiac synovial, abestosis and, 986 (letter)

childhood, classification of, 2579

Ewing, radiographic and computed tomographic features of, prognosis and, 988 (letter)

of head and neck, prognostic factors in, 697

osteogenic, bone morphogenetic proteins in, immunohistochemical detection of, 842

soft tissue, bone morphogenetic proteins in, immunohistochemical detection of, 842

Screening

for breast cancer. *See* Mammography

for colorectal cancer, 2023

in elderly, overcoming barriers to, 2190, 2194

future directions in, 1482

for lung cancer, tumor markers in, 1652 (letter)

for neuroblastoma, 3223

for prostate cancer, 3077 (editorial), 2017. *See also* Prostate specific antigen

reduction of low-yield biopsies in, 3146

test comparisons for, 1516 (editorial), 1615

psychosocial issues in, 1464, 1474, 1482

Transtheoretical Model for, 1482

Senescence, biologic aging and, 2092

Sex, esophageal cancer survival and, 2425

Single photon emission computed tomography, for brain tumors, 3080 (editorial), 3190

Skin

radiation changes in, causes of, 3063

T-cell lymphoma of, angioimmunoblastic lymphadenopathy with dysproteinemia and, 1801

Skin cancer, *bcl*-2 protein in, 1720

Skull base chordoma, clinicopathology and treatment of, 2261

Small cell carcinoma, of prostate, neurologic complications in, 3159

Small cell tumor

of lung. *See* Lung cancer, small cell

metastatic neuroendocrine anaplastic, in multiple endocrine neoplasia type 1, 2374

Small intestinal disease, immunoproliferative, Epstein-Barr virus infection and, 1699

Small intestine, radioprotection of, with topical WR-2721, 2379

Smoking

cessation strategies for, for elderly, 2051, 2055, 2062

histology-based lung cancer incidence and, 1556

public health strategies for, 1423

synchronous and metachronous head and neck cancer and, 1933

Soft tissue hemangiomas, in Maffucci's syndrome, neuropeptides and, 949

Soft tissue sarcoma, bone morphogenetic proteins in, immunohistochemical detection of, 842

Soft tissue tumors, mediastinal, smooth muscle tumors presenting as, 2251

Soluble interleukin-2 receptor

in gastric cancer, 2745

in non-Hodgkin lymphoma, treatment failure and, 1792

Somatostatin, in paraganglioma, 142

Southwest Oncology Group Breast Cancer Committee, current trials and future directions of, 1132

S-phase fraction, in breast cancer, prognosis and, 381, 1752, 2287

Spinal cord toxicity, of intensive CNS therapy, 3034

Splenectomy, in non-Hodgkin's lymphoma, 933

Splenic lymphoma with villous lymphocytes, leukemic meningitis in, 61

Squamous cell carcinoma. *See also specific sites*

of cervix, squamous cell carcinoma antigen and tumor size in, 2497

of esophagus. *See* Esophageal cancer

of head and neck. *See* Head and neck cancer

lingual, grading of, 789

oral, nucleolar organizer regions in epithelium adjacent to, 3071 (letter), 3245 (letter)

of skin, *bcl*-2 protein in, 1720

of vulva, lymph node variables in, prognosis and, 2399 (editorial), 2491

Squamous cell carcinoma antigen, in cervical squamous cell carcinoma, 2497

Squamous epithelial dysplasia, with squamous cell carcinoma, of esophagus, 2889

Staging

of prostate cancer, 1 (editorial)

TNM, for prostate cancer, 104

trends in, National Cancer Data Base report on, 1974

Stem cell transplant, with single-cycle high-dose cyclophosphamide, for relapse, 715

Stereotactic radiosurgery, for recurrent glioma, 1342

Steroid hormones, breast cancer and, 1111

Stomach. *See also under* Gastric

intestinal metaplasia of, 556

Stromelysin-3, in breast cancer, 1045

- Substance P, in Maffucci's syndrome, 949
- Supracricoid partial laryngectomy, for glottic cancer, 2781
- Suprasellar germinomas, chemotherapy for, aqueous vasopressin for diabetes insipidus in, 2589
- Suramin, for prostate cancer, renal toxicity in, 1612
- Surgery. *See also specific sites and types*
- for anaplastic thyroid cancer, 1348
 - for bladder cancer, radiotherapy prior to, 2819
 - for breast cancer. *See* Breast conservation; Mastectomy
 - for cerebral hemisphere glioma, 1784
 - clinical trials of. *See* Clinical trials
 - for colorectal cancer, in elderly, 2147
 - cytoreductive, for advanced ovarian cancer, 656
 - in elderly, 2107
 - for esophageal cancer, 1680
 - for gastrointestinal emergencies, in children undergoing chemotherapy, 203
 - for glottic cancer, 2781
 - for hepatocellular carcinoma, prognosis after, 2772
 - for medulloblastoma/posterior fossa primitive neuroectodermal tumors, IQ declines after, 965
 - for non-small cell lung cancer, with etoposide and radiation therapy, 1253
 - postchemotherapy, for nonseminomatous germ cell tumors, 1329
 - for pulmonary metastases, late survival after, 2791
 - for renal cell carcinoma, in von Hippel-Lindau disease, 2541
 - for uveal melanoma, 3073 (letter)
- Surgical quality assurance, in clinical trials, 2630
- Sweden, breast cancer clinical trials in, 1156
- Symptom control, in psychosocial oncology, 1438, 1458
- Synovial sarcoma, cardiac, abestosis and, 986 (letter)

T**Tamoxifen**

- for breast cancer
 - in adjuvant therapy, 401
 - clinical trials of, 1132, 1135, 1139, 1150, 1156, 1160
 - in elderly, 2165
 - insulin-like growth factor and, 618
 - with photoproducts, 1725
 - for prevention, 2726
 - effect of on lipid peroxide and antioxidative system, in postmenopausal breast cancer, 78
 - for male breast cancer, side effects of, 74
- Targeted toxins, as anticancer agents, 1006
- Taxotere, for breast cancer, clinical trials of, 1135
- T-cell lymphoma
- B-cell malignancy after, 164
 - cytokine abnormalities and autologous mixed lymphocyte reaction in, 2843
 - of skin, angioimmunoblastic lymphadenopathy with dysproteinemia and, 1801

T cells

- p55/p75 interleukin-2 receptor expression by, 2562
 - tumor-infiltrating cytolytic, in breast cancer, 1275
- Temozolomide, for breast cancer, 1164

Testicular cancer

- in blacks, 1649 (letter)
- germ cell
 - early-stage, prognostic factors in, 1335
 - resection of residual masses and retroperitoneal lymphadenectomy for, 1329

Thallium imaging, of brain tumors, 3080 (editorial)**Thiotepa, for breast cancer, clinical trials of, 1156****Third party payment**

- for breast cancer experimental therapies, 491
- for care of elderly, 2200, 2204
- for clinical trials, 2662

Thymoma

- argyrophilic nucleolar organizer regions in, prognosis and, 1568
- delta-T lymphocytosis in, 2924
- subclassification of, 542 (editorial)
- prognosis and, 606

Thyroid cancer

- anaplastic, treatment of, 1348
- follicular
 - diagnosis, treatment, and outcome in, 985 (letter)
 - with insular component, 2599 (letter)
- medullary
 - N-myc immunoreactivity in, prognosis and, 134
 - with thyroglobulin immunoreactivity, in sporadic multiple endocrine neoplasia type 2B, 928
- papillary, with insular component, 2599 (letter)
- pediatric, after Chernobyl disaster, 748

T-lymphoblastic disease, recurrent, interferon alpha-2B for, in children, 197**delta-T lymphocytosis, in thymoma, 2924****TNM staging system, for prostate cancer, 104****TNP-470, for breast cancer, 1164****Tomography, positron emission. *See* Positron emission tomography****Topoisomerase II inhibitors, cytotoxic activity of, 2857****Topotecan, for breast cancer, 1164****Total parenteral nutrition, glutamine supplementation in, for drug toxicity, 2879****tRA, for breast cancer, 1164****Transcatheter arterial embolization, with/without cisplatin, for hepatocellular carcinoma, 2449****Transcatheter oily chemoembolization, for hepatocellular carcinoma, 16****Transcutaneous oxygen pressure, after radiation therapy, 3063****Transforming growth factor-beta, in ovarian cancer, 90****Translational research, behavioral science in, 1409****Transplacental carcinogenesis, 1674****Transplant**

- autologous stem cell, with single-cycle high-dose cyclophosphamide, for relapse, 715
- bone marrow
 - in advanced neuroblastoma, 972
 - for breast cancer, reimbursement for, 491
 - with high-dose melphalan, for multiple myeloma, 2930
 - radiation-induced hematologic toxicity and, in breast cancer, 2956

with single-cycle high-dose cyclophosphamide, for relapse, 715

lymphoproliferative disease after, 1959, 2436

Transtheoretical Model, for screening, 1482

Transverse rectus abdominis flap, cancer recurrence in, mammographic detection of, 2804

Treatment, clinical trials of. *See* Clinical trials

Tumor markers. *See also specific markers*

in lung cancer screening, 1652 (letter)

U

Ultrasonography

color Doppler, for gestational trophoblastic disease, 2361

in postmenopausal pelvic mass diagnosis, vs. CA-125 and pelvic exam, 1398

United Kingdom Co-ordinating Committee on Cancer Research breast cancer trials, 1160

Urogenital sinus mesenchyme, in prostate development/carcinoma, 1031

Urokinase plasminogen activator, in breast cancer, prognosis and, 2276

Urothelial transitional cell carcinoma, recurrent/metastatic, chemotherapy response and prognosis in, 123

Us Too support group, for prostate cancer, 2188

Uterine cancer

nucleolar organizer regions in, 3142

papillary serous adenocarcinoma, p53, *c-erbB-2*, and DNA in, 1778

Uveal melanoma, management of, 3073 (letter)

V

Vasopressin, aqueous infusion of, during chemotherapy in diabetes insipidus, 2589

Verapamil

hepatic artery infusion of, doxorubicin concentration and, 810

intrahepatic, for multidrug resistance, 2757

Veterans Administration clinical trials, 2701

Vinblastine

for Hodgkin's disease, 159

for Mediterranean Kaposi's sarcoma, in elderly, 2783

preoperative, for melanoma, 2476

Vincristine

for angiomatoid malignant fibrous histiocytoma, 962

for breast cancer, clinical trials of, 1135

for Burkitt's leukemia, in HIV-positive patient, 1261

for non-Hodgkin's lymphoma, 3029, 2657

for retinoblastoma with orbital involvement, 722

Vinorelbine, for breast cancer, clinical trials of, 1135, 1164

Viral infections, oncogenic, perinatal infection with, 1675

Vitamin K-dependent γ -carboxylation, in hepatocellular cancer, 1533

Vitamins, prenatal, medulloblastoma incidence and, 3240

Vomiting

controlled release vs. immediate release metoclopramide for, 3204

odansetron vs. granisetron for, 1945

Von Hippel-Lindau disease, renal cell carcinoma in, conservative surgery for, 2541

VP-16, oral, for prostate cancer, 100

Vulvar cancer, squamous cell, lymph node variables in, prognosis and, 2399 (editorial), 2491

W

Weight, breast cancer and, 288, 632, 1090

White matter changes, with cranial irradiation, 2828

Wilms' tumor

clinical trials for, 2710

microsubstaging variables, patient age, and tumor weight in, 1817

telomere fusion in, 767

WR-2721, topical, for radioprotection of small intestine, 2379

Z

ZEBRA (Epstein-Barr virus BZLF-1 replication activator), IgA antibody against, in nasopharyngeal cancer, prognosis and, 2414

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Act of August 2, 1970: Section 3685, Title 39 United States Code) Date of Filing—October 1, 1994; Title of Publication—Cancer; Frequency of Issue—Twice Monthly; Annual Subscription Price—\$135.00; Location of Known Office of Publication—12107 Insurance Way, Suite 114, Hagerstown, MD 21740; Location of Headquarters or General Business Offices of the Publisher—J.B. Lippincott Company, 227 East Washington Square, Philadelphia, PA 19106; Publisher—American Cancer Society, 1599 Clifton Road NE, Atlanta, GA 30329; Editor—Robert V. P. Hutter, MD, 101 Old Short Hills Road, Suite 503, West Orange, NJ 07052-1023; Managing Editor—Diane Scott-Lichter, 101 Old Short Hills Road, Suite 503, West Orange, NJ 07052-1023; Owner—American Cancer Society, 1599 Clifton Road NE, Atlanta, GA 30329; Known Bondholders, Mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities—None. A. Total no. copies printed (*net press run*), average 16,764, actual 17,200; B. Paid circulation 1. Sales through dealers and carriers, street vendors and counter sales, average none, actual none; 2. Mail subscriptions, average 13,513, actual 14,435; C. Total paid circulation, average 13,513, actual 14,435; D. Free distribution by mail, carrier or other means. Samples complimentary, and other free copies, average 459, actual 476; E. Total distribution (*sum of C and D*), average 13,972, actual 14,911; F. Copies not distributed 1. Office use, leftover, unaccounted, spoiled after printing, average 2,792, actual 2,289. Returns from news agents, none; G. Total (*sum of E and F—should equal net press run shown in A*), average 16,764, actual 17,200. I certify that the statements made by me above are correct and complete. Virginia B. Martin, *Vice President, Journals*.

Authors' Index—Volume 74

A

Abdulla, M., 1739
 Abe, M., 3108
 Abe, S., 46, 2245
 Abed, S., 164
 Abel, K. J., 1013
 Abel, P. D., 1607
 Abner, A., 1746
 Abrams, J. S., 1164
 Abu-Eshy, S., 2843
 Adachi, H., 2984
 Adachi, K., 2984
 Adachi, Y., 1230
 Adamson, P. C., 1627
 Adelstein, D. J., 1680
 Adler, L. M., 1891
 Agostini, C., 2562
 Aguiar, M., 2935
 Ahluwalia, S. M., 789
 Ahn, C., 1575, 2139
 Aihara, T., 872, 1595
 Aizawa, K., 4
 Akagi, Y., 1863
 Akaogi, E., 3113
 Akatsuka, N., 1939
 Akiyama, F., 2281
 Akiyoshi, T., 3108
 Alaibac, M., 1801
 Alan Coates for the International Breast
 Cancer Study Group, 1139
 Alapetite, C., 2352
 Albers, P., 1335
 Alberti, A., 2442
 Albrecht, T., 1458
 Albright, A. L., 1827
 Alderman, E., 842
 Alfano, R. M., 134
 Ali, M. K., 182
 Allen, J. C., 940
 Allen, S., 2118
 Altungoz, O., 2268
 Alvarez-Sala, R., 1552
 Amiel, A., 2924
 Anania, C., 1874
 Andersen, B. L., 1484
 Andersson, S., 2347
 Andolenko, P., 1933
 Andreasen, P. A., 2276
 Anelli, A., 74
 Angus, P., 2436

Appelbaum, F. R., 715
 Aprikian, A. G., 1329, 1768
 Arase, Y., 2918
 Arber, D. A., 1899
 Arcicasa, M., 978
 Ardalán, B., 1869
 Ardouin, P., 810
 Arias-Díaz, J., 1546
 Armes, J. E., 2436
 Arver, S., 142
 Asbell, S. O., 2828
 Asmar, L., 2579
 Ater, J. L., 203
 Audigier, J.-C., 599
 Averette, H. E., 545
 Ayash, L. J., 532
 Aynaud, O., 1762
 Aziz, N. M., 632

B

Baba, H., 1230
 Babaian, R., 3146
 Babul, N., 1808, 3204
 Bacchetti, S., 900
 Badalament, R., 1615, 3146
 Baddoura, F. K., 1699
 Bader, R., 16
 Badokhon, N. H., 2321
 Badwe, R. A., 2425
 Baert, L. V., 3164
 Baidas, S., 2516
 Baile, W. F., 336
 Baines, C. J., 1207
 Baird, A., 848
 Bairey, O., 774
 Bajorin, D. F., 1329
 Bakal, C. W., 1706
 Baker, T. R., 656
 Baki, W., 1546
 Bal, D. G., 2067
 Balch, C. M., 2476
 Baldeyrou, P., 2791
 Balibrea, J. L., 1546
 Balis, F. M., 1627
 Ballard-Barbash, R., 1090
 Balleari, E., 2300
 Balzi, D., 3126
 Banks, E. R., 2533
 Barba, D., 1342
 Barbara, L., 1713
 Barbarisi, L. J., 1289
 Barbieri, R. L., 1318
 Barchielli, A., 3126
 Barker, R. L., 1959
 Barnhill, R. L., 2935
 Barone, A., 1927
 Barrasso, R., 1762
 Bartel, J., 945
 Barthelemy, C., 599
 Bash, R. O., 189
 Bason, C., 2300
 Basset, P., 1045
 Bassett, L. W., 2804
 Bassot, V., 2781
 Bast, R. C., 93
 Batsakis, J. G., 152
 Battaglia, S. E., 2436
 Battezzati, P. M., 134
 Battifora, H., 1575
 Baußmann, E., 648
 Baxevanis, C. N., 1275
 Beckwith, J. B., 1817
 Begg, C., 697
 Beitz, J., 848
 Belghiti, J., 1533
 Bell, N., 1607
 Belldegrün, A., 1904
 Bellg, A. J., 1409
 Bellino, J., 1927
 Bellocq, J.-P., 1045
 Beltangady, M. S., 2579
 Ben-Bassat, I., 3029
 Bengmark, S., 2454
 Benjamin, R. S., 1265, 2476
 Benner, S. E., 2719
 Benniston, A. C., 1725
 Benoit, B. G., 1915
 Bensinger, W. I., 715
 Benson, M. C., 1667
 Benvegnù, L., 2442
 Berchuck, A., 93
 Bergan, R. C., 1612
 Berger, B. E., 440
 Berger, C., 1283
 Berger, M. S., 1784
 Bergqvist, L., 2454
 Berkman, B., 2004
 Bernini, J. C., 962
 Bertino, J., 2757
 Bertino, J. R., 2224

- Beynon, G., 90
 Bezeaud, A., 1533
 Bhansali, M. S., 2425
 Bhat, D., 1927
 Bianchi, S., 3126
 Bicknell, R., 1021
 Bigard, M.-A., 16
 Bignon, J., 2460
 Black, P., 3190
 Blackwell, S., 1243
 Blake, M., 740
 Blake, M. A., 203
 Blanchard, C. G., 1458
 Bland, K. I., 350
 Blaney, S. M., 1627
 Blasco, R., 1552
 Bloom, J. R., 1464
 Blot, W. J., 1686
 Bodis, S., 708
 Body, G., 1283
 Boente, M., 2979
 Boeryd, B., 2329
 Bognel, C., 810
 Boissel, P., 16
 Bolande, R. P., 1674
 Bolondi, L., 1713
 Bonadonna, G., 2483
 Bonavida, B., 2546
 Boneschi, V., 2873
 Bonfrer, J. M. G., 2307
 Bonham, V. L., 271
 Bonsack, M. E., 2379
 Borchard, F., 2218
 Borden, J. D., 2991
 Borgen, P. I., 74
 Boring, C. C., 222
 Bortolus, R., 978
 Bosl, G. J., 1329
 Boudjema, K., 16
 Bougnoux, P., 1283
 Boutin, C., 2460
 Bow, E. J., 52
 Bowman, L. C., 733, 2593
 Boyd, J., 2215
 Boyett, J. M., 1827
 Boyle, P., 1556
 Bozeman, P., 1953
 Bradley, L., 2341
 Braly, P. D., 664
 Brambilla, L., 2873
 Brasitus, T. A., 2908
 Brasnu, D., 2781
 Brawley, O. W., 2726
 Brawn, P. N., 1607
 Brechot, J.-M., 38
 Brennan, M. F., 697
 Brenner, R. J., 486
 Breslow, N. E., 1817
 Bretton, P. R., 2991
 Brien E. W., 1253
 Brigandi, A., 2791
 Brizel, D. M., 159
 Brody, L. C., 1013
 Bronowicki, J.-P., 16
 Brouland, J.-P., 3042
 Brown, S. J., 3190
 Browning, S., 2949
 Brucks, J. P., 1318
 Bruera, E. D., 3204
 Brun, J., 38
 Brunner, K. W., 1139
 Bruzzi, P., 2300
 Bryant, W. P., 2589
 Buchanan, G. R., 189, 0197
 Buckner, C. D., 715
 Bueschen, A., 916
 Bui, H. X., 2811
 Buiatti, E., 3126
 Burditt, L. J., 25
 Burgess, A., 1265
 Buring, J. E., 1837, 2625
 Burish, T. G., 1408, 1438, 2676
 Burklow, J., 2194
 Burshtein, D., 949
 Butler, J. J., 3083
 Buyske, J., 1289
 Buzaid, A. C., 2476
 Byers, T., 288
 Byrne, C., 301
 Byrne, M., 1139

C
 Caffier, H., 1398
 Cain, D., 2208
 Calais, G., 1283
 Caldwell, S. A., 203
 Callender, T., 152
 Camburn, J. F., 263
 Camus, M. G., 1289
 Cannata, G., 1945
 Canpolat, C., 3059
 Cappellari, J. O., 1355
 Capron, F., 38
 Carbone, A., 978
 Carey, W. P., Jr., 3118
 Carlson, G. W., 436
 Carrie, C., 2352
 Carter, C. L., 2208
 Casaretti, R., 1874
 Casassus, P., 2930
 Cash, J. V., 189
 Castellanos, R. D., 2991
 Castiglione, M., 1139
 Catalona, W. J., 1516
 Cauchois, R., 2781
 Cavalli, F., 1139
 Cavazzana, A., 2579
 Cecchetto, A., 2442
 Cedermark, B., 142
 Cerutti, A., 2562
 Cetto, G. L., 2562
 Cha, S. S., 1752
 Chabner, B. A., 780
 Chamberlain, M. C., 1342, 1912
 Chambers, J. T., 1323
 Chambers, S. K., 1323
 Chambon, P., 1045
 Chamness, G. C., 1601
 Champion, V., 329
 Chan, C. H., 174
 Chan, J. K. C., 174
 Chan, L. C., 174
 Chan, T. K., 174
 Chandrasekharappa, S. C., 1013
 Chang, J., 3135
 Chang, J.-M., 2449
 Chapet, S., 1283
 Chastang, C., 38
 Chayama, K., 2918
 Cheang, M. S., 52
 Chemello, L., 2442
 Chen, C.-A., 2361
 Chen, C.-L., 2361
 Chen, F.-C., 2361
 Chen, M. S., Jr., 1503
 Chen, T.-M., 2361
 Chen, Y., 1556, 2239
 Chen, Z., 1662
 Cheng, A. K. P., 2414
 Cherlow, J. M., 1827
 Chesley, A., 1615
 Chetrit, A., 3029
 Chevres, A., 3190
 Chew, K., 1000
 Chiarle, R., 1568
 Chiba, S., 1634
 Chieco, P., 1713
 Chik, C. L., 928
 Chiu, E. K. W., 174
 Chiusa, L., 1568
 Chivato, T., 1552
 Chlebowski, R. T., 2734
 Cho, R., 1634
 Chodak, G. W., 2178
 Choi, N., 606
 Chou, C.-Y., 2497
 Chougule, P. B., 1927
 Chu, A. C., 1801
 Chu, K. C., 301
 Chu, Q. D., 1927
 Chung, L. P., 30
 Cipolla, C., 1945
 Clark, R. A., 632, 2366
 Clinch, J. J., 52
 Coakham, H. B., 3240
 Cobau, C. D., 2694
 Cochet, C., 2414

Coffey, D. H., 733
 Coffield, K. S., 1899
 Coggi, G., 134
 Cohen, A. M., 2224
 Cohen, C., 2935
 Cohen, H., 1383
 Cohen, H. J., 2092
 Cohen, M. B., 1621
 Cohen, M. K., 1899
 Cole, D., 2341
 Coleman, N., 884
 Collins, F. S., 1013
 Collins, J., 1139
 Colombat, P., 2930
 Comella, G., 1874
 Comella, P., 1874
 Connolly, J. L., 1746
 Contesso, G., 864
 Conway, T., 1184
 Copps, S. W., 3010
 Copper, M. R., 362, 1612
 Corn, B. W., 2828, 2979
 Cornillie, F., 1398
 Cortes-Funes, H., 1139
 Costantino, J., 2638
 Costanza, M. E., 2009, 2046
 Cottier, M., 599
 Couch, F. J., 1013
 Cowan, K., 2808
 Cox, C. E., 336
 Crabtree, W. N., 1335
 Cramer, D. W., 1309, 1318
 Crawford, E. D., 916, 2182, 3002
 Crawford, J., 159, 1243
 Crombach, G., 1398
 Cross, P., 2491
 Cross, P. A., 90
 Crossett, L. S., 565
 Cuilleron, M., 599
 Cumberlin, R. K., 2516
 Cummings, G., 1217
 Cummings, G. D., 100
 Cummings, K. M., 2062
 Cunha, G. R., 1030
 Curcio, C., 1874
 Curran, W. J., Jr., 2828
 Curtis, M. A., 2541
 Curto, G., 1945
 Cuzick, J., 1160
 Cynamon, J., 1706

D

Dabouis, G., 2460
 Dadparvar, S., 3190
 Dallal, G. E., 893
 Dallavalle, G., 2873
 Daly, P. A., 2374
 Damasio, E., 1792
 Dammacco, F., 1792

Dämmrich, J., 1525
 D'Angio, G. J., 1817
 Daniel, W. E., 740
 Daponte, A., 1874
 Daras, V., 90
 Darke, A. C., 1808, 3204
 DaRosso, R. C., 940
 Dautzenberg, B., 38
 Davis, R. L., 1921
 Dawsey, S. M., 1686
 DeAntoni, E. P., 2182
 Deapen, D., 1474
 Debus, S., 1525
 Dedoussis, G. V. Z., 1275
 deKernion, J. B., 1904
 Dekker, A. W., 703
 Delaisements, C., 38
 Delaney, J. P., 2379
 Delarue, J.-C., 864
 Deliganis, A. V., 1784
 Del Mastro, L., 2300
 del Rosario, A. D., 2811
 Demaille, M.-C., 2352
 Demetri, G. D., 1887
 Demirer, T., 715
 de Mulder, P. H., 2850
 Deng, G., 1000
 De Paoli, A., 978
 de Paredes, E. S., 342
 de Riese, W. T., 1335
 Desai, P. B., 2425
 Descamps, P., 1283
 Desjardins, L., 722
 de Terreros, F. J. G., 1552
 Deutsch, M., 1243
 De Vataire, F., 1933
 De Witte, O., 2836
 Dhaliwal, H., 1808
 Dinney, C. P., 2819
 DiPetrillo, T., 878
 Dispensa, E., 1792
 Dobbins, J., 1784
 Dockter, M., 3142
 Dodd, G. D., Jr., 239
 Doffoel, M., 16
 Donahue, B., 940
 Donis-Keller, H., 1584
 Donnelly, W. H., 1237
 Donofrio, K., 1869
 Donohue, J. P., 1335
 Dose, A. M., 945
 Douglass, E. C., 2593
 Douillard, J.-Y., 2460
 Doz, F., 722
 Drane, W. E., 1193
 Dressler, L., 381
 Droller, D. G., 1261
 Dubner, S., 697
 du Bois, A., 2509

Duda, R. B., 1746
 Duffy, M. J., 2276
 Dufier, J.-L., 722
 Dumas, F., 16
 Duncan, E., 1915
 Dunne, F. P., 83
 Dupont, W. D., 1204
 Dwyer, J. T., 1125
 Dyba, T., 1591

E

Eberlein, T. J., 376, 1746
 Edwards, B., 2101
 Efird, J., 606
 Efird, J. T., 2261
 Eisner, E. J., 2194
 Elder, D. E., 3118
 Elgamal, A. A., 3164
 Eliasiewicz, M., 686
 Elledge, R. M., 1601
 El-Naggar, A. K., 152, 2476
 Emi, M., 2281
 Endo, C., 2239
 Endo, K., 1230
 Endo, M., 578
 Engaräs, B., 2749
 Engstrom, P. F., 1433
 Enker, W., 2224
 Enthammer, C., 2562
 Erban, J. K., 878
 Eriksson, E., 376
 Esteban, J. M., 1575
 Ettinghausen, S., 2808
 Evans, W. P., 2991
 Ewer, M. S., 182

F

Fair, W. R., 1768
 Fallon, B., 2541
 Farniok, K. E., 2154
 Farr, G. H., Jr., 2956
 Fattovich, G., 2442
 Felder, B., 1575
 Felemovicius, I., 2379
 Feng, L.-J., 440
 Fennelly, J. J., 2276
 Ferrell, B. A., 2139
 Ferrell, B. R., 2139
 Fields, J. N., 466
 Figg, W. D., 1612
 Figge, H., 2811
 Figlethaler, W. M., 2996
 Figlin, R., 1904
 Finlay, J. L., 1827
 Finzi, A. F., 2873
 Fischman, A. J., 3080
 Fisher, E. R., 2638
 Fisher, H. A. G., 2811
 Fisher, R. I., 2657

- Flaherty, L. E., 100
 Flanagan, R. C., 916
 Flannery, J., 1556
 Flax, S., 3142
 Flejou, J.-F., 1533
 Flejter, W. L., 1013
 Fleming, I. D., 733, 2160, 2662
 Fleming, M. D., 2160
 Fletcher, C. D. M., 3227
 Floyd, C. E., Jr., 2944
 Foley, K. M., 907
 Fontanesi, J., 733
 Forbes, J. F., 1139
 Ford, L. G., 2726
 Foreman, N. K., 3240
 Forman, W. B., 2151
 Fort, D. W., 962
 Fossati, S., 2873
 Foster, R. S., 1335
 Foster, W., 1243
 Fotopoulos, S. S., 1367
 Fox, S., 1021
 Fox, S. A., 625, 2028
 Fracasso, P. M., 466
 Fram, R. J., 2949
 Franceschi, T., 2562
 Franchin, G., 978
 Frankenthaler, R., 152
 Fransson, P., 2520
 Frei, E., III, 2610
 Freidlin, B., 2208
 Fried, G., 142
 Friedman, M., 1164
 Friedman, M. A., 2208
 Frierdich, S., 3034
 Fristedt, S., 2329
 Frutos, A., 3063
 Frykberg, E. R., 350
 Fu, Y. S., 2804
 Fuchimoto, S., 3097
 Fujii, S., 2321
 Fujimoto, T., 972
 Fujimura, S., 2239
 Fujishima, M., 12, 2430
 Fujiwara, T., 1634
 Fukui, M., 3176
 Fukumoto, M., 2546
 Fung, E., 1629
 Fuqua, S. A. W., 1026
 Furman, W. L., 733
 Fürst, P., 2879
 Furui, T., 2555
 Furukawa, H., 1855
 Furukawa, R., 2234
 Furukawa, Y., 795
 Furusawa, M., 2889
 Furuta, A., 1294
 Fuseya, T., 2555
- G**
 Gaarenstroom, K. N., 2307
 Gabbert, H. E., 2218
 Galian, A., 3042
 Galieni, P., 1792
 Gallee, M. P. W., 2307, 2314
 Galligioni, E., 1139
 Gamel, J. W., 2483
 Ganju, V., 920
 Ganz, P. A., 1445, 2620
 Garamvoelgyi, E., 854
 Garcia, D., 2781
 García, C., 1546
 García Río, F. J., 1552
 García Satué, J. L., 1552
 Garfinkel, L., 222
 Garin-Chesa, P., 842
 Garrone, O., 2300
 Garver, R. I., Jr., 1584
 Gaspar, L. E., 1217
 Gebbia, N., 1945
 Gebbia, V., 1945
 Gebhard, S., 854
 Geddes, M., 3126
 Gehan, E. A., 2579
 Geisinger, K. R., 1355, 3227
 Gelber, R. D., 1139
 Gelman, R., 1746
 George, S., 2949
 Ghio, R., 2300
 Ghosh, C., 945
 Gibbs, H. R., 182
 Gibertini, M., 336
 Giorgi, D., 3126
 Girard, P., 2791
 Giuliano, A., 893
 Given, B., 2071
 Given, B. A., 2128
 Given, C. W., 2071, 2128
 Glatstein, E., 477
 Glover, D., 2949
 Gnepp, D. R., 748
 Gockerman, J. P., 159
 Goey, S. H., 2850
 Goggins, M. G., 2374
 Goldberg, H. I., 565
 Goldhirsch, A., 1139
 Goldin, B. R., 1125
 Goldman, S., 2836
 Goldwein, J. W., 965
 Gonchoroff, N. J., 1752
 Gonzales-Crussi, F., 2579
 Goodman, Z. D., 2765
 Goosen, L. S., 767
 Gorbach, S. L., 1125
 Gorczyca, D. P., 2804
 Gordon, S. G., 1367
 Gotteland, M., 864
- Gouchi, A., 3097
 Gouyett, A., 810
 Graff, K. L., 182
 Graham, M. L., 453
 Graham, S. D., Jr., 3077
 Gramantieri, L., 1713
 Grant, C., 1752
 Grassel, S., 1525
 Greco, F. A., 1377
 Green, D. M., 1817
 Greenberg, A. L., 1261
 Greenberg, E. R., 2885
 Greffe, B. S., 203
 Grehan, D., 1693
 Greven, K. M., 1303, 1355
 Grill, J. P., 2956
 Grimelius, L., 134, 0142
 Gritz, E. R., 1423
 Grosvenor, M., 2734
 Gruber, M. L., 1383
 Grunenwald, D., 2791
 Gualtieri, L. J., 1125
 Gudgeon, A., 1139
 Guerin, J.-C., 2460
 Guerrieri, C., 2329
 Guerry, D., IV, 3118
 Guillin, M.-C., 1533
 Guillou, L., 854
 Guleria, A., 3212
 Gulliyya, K. S., 1725
 Gunderson, L. L., 537
 Gupta, A., 2516
 Gustafson, G. S., 640
 Gustavsson, B., 2749
- H**
 Haase, G. M., 203, 0740, 2630
 Hachitanda, Y., 3223
 Hadar, H., 774
 Hadji, M. H., 854
 Hafström, L., 2749
 Hagen, N., 1808
 Haggitt, R., 1225
 Haie-Meder, C., 2352
 Hainsworth, J. D., 1377
 Hajdu, S. I., 697
 Hakes, T., 907
 Hales, M. L., 1739
 Hallquist, A., 1348
 Halperin, N., 949
 Halpern, A., 3118
 Halpern, E., 1196, 1212
 Hamberger, B., 142
 Hammarsten, J., 2347
 Hamoudi, A. B., 2579
 Hank, G. E., 2174
 Hanks, G. E., 3198
 Hanlon, A., 2174
 Hanlon, A. L., 3198

Hannisdal, E., 933
 Hantschmann, P., 2502
 Hara, T., 3023
 Harada, Y., 2281
 Harlow, B. L., 1318
 Harms, D., 2579
 Harousseau, J. L., 2930
 Harriman, A., 1725
 Harris, A. L., 1021
 Harris, J. R., 1746
 Harris, M., 3135
 Harris, N. L., 606, 1383
 Harrison, L. B., 697
 Harsanyi, Z., 1808, 3204
 Hart, A. A. M., 2307
 Hart, J., 2908
 Hartmann, L. C., 2956
 Hartmann, W. H., 301
 Hasegawa, R., 1063
 Hashimoto, T., 2745
 Hata, J.-i., 3223
 Hatakeyama, K., 4
 Hatch, K. D., 893
 Hathorn, J. W., 159
 Hathorn, R. W., 1904
 Havlik, R. J., 2101
 Hayashi, K., 573
 Hayden, C. L., 1323
 Haynes, H., 1706
 Hays, H., 1808
 Headlee, D., 1612
 Healey, J. H., 842, 1253
 Heath, C. W., Jr., 222, 2885
 Heath, D. A., 83
 Heesemann, J., 1525
 Helmerhorst, T. J. M., 2307, 2314
 Hempling, R. E., 656
 Henderson, I. C., 401
 Hendricks, J. B., 1237
 Hennekens, C. H., 1837, 2625
 Hennessy, T. P. J., 1693
 Henson, D. E., 424, 1974, 2385
 Henzen-Logmans, S. C., 2850
 Herndon, J., 1243
 Herr, H. W., 1329
 Herskovic, A. M., 1217
 Herskovitz, P., 774
 Hertzmark, E., 1125
 Herzog, T. J., 1891
 Hess, J. L., 708
 Hibbert, J., 789
 Hickey, K., 1693
 Hickok, J. T., 2676
 Hida, J.-I., 592
 Higgs, D., 3104
 Hildebrand, J., 2836
 Hilsenbeck, S. G., 1601
 Hirasawa, Y., 2798
 Hirte, H. W., 900

Hiyama, E., 1821
 Hiyama, K., 1821
 Hizawa, K., 2430
 Ho, R. C. S., 2739
 Hochberg, F. H., 1383, 3080
 Höckel, M., 648
 Hoen, H. M., 1303
 Hoffstetter, S., 2352
 Högberg, T., 2329
 Högstedt, B., 2347
 Holford, T. R., 1556
 Holmberg, S. B., 2749
 Holmén, A., 2347
 Homesley, H. D., 2399
 Hong, W. K., 2719
 Höög, A., 142
 Hoppe, R. T., 3198
 Hordijk, G. J., 703
 Horstmann, O., 2218
 Hortobagyi, G. N., 416
 Hoshino, T., 1921
 Hoskins, W. J., 907
 Houghton, J. A., 2593
 Howe, G. R., 1078
 Howell, A., 3135
 Howell, S. B., 664
 Howlett, N., 2593
 Hrushesky, W. J. M., 2701
 Hsieh, C.-Y., 2361
 Hsieh, F.-J., 2361
 Hug, E., 606
 Hughes, K. S., 1289
 Huisse, M.-G., 1533
 Hulka, B. S., 1111
 Hulka, C. A., 1196, 1212
 Humphrey, J., 1612
 Humphreys, S., 2533
 Hunter, D. J., 1085
 Hunter, W. M., 2979
 Hurdebourcq, J.-P., 38
 Hürny, C., 1139
 Hurteau, J., 93
 Hurwitz, C., 1953
 Hussain, M. H., 100
 Hussein, A., 1360
 Huvos, A. G., 842, 1253

I

Ichihashi, M., 1720
 Ichikawa, T., 1821
 Ichiki, M., 66
 Iida, K., 2555
 Iida, M., 12, 2430
 Iishi, H., 826
 Iizuka, T., 1634
 Ikeda, K., 2918
 Ikeda, Y., 1939
 Imai, A., 2555
 Imaoka, S., 872, 1595, 1855

Inage, Y., 3113
 Inaji, H., 872, 1595
 Ingle, J. N., 1733, 1752, 2956
 Ingold, J. A., 640
 Inoue, K., 46, 0817, 2245
 Ionesco, M., 1762
 Ip, C., 1050
 Ishak, K. G., 2765
 Ishida, A., 1939
 Ishida, K., 2745
 Ishiguro, S., 826
 Ishikawa, O., 826, 1855
 Ishikawa, S., 3113
 Ishikawa, T., 2896
 Ishimoto, K., 3223
 Isobe, H., 46, 2245
 Isomoto, H., 1863
 Itakura, Y., 795
 Itho, T., 817
 Ito, H., 3023
 Ito, I., 2281
 Ito, N., 1063
 Ivanyi, D., 2314
 Iwaki, T., 3176
 Iwasaki, H., 66
 Iwata, M., 972
 Izraeli, S., 1627

J

Jackson, R. N., 2200
 Jaffe, E. S., 3051
 Jaffe, N., 3059
 James, W. D., 3051
 Jani, P., 789
 Janicek, M., 545
 Janisch, L., 1965
 Jarrett, A. R., 632
 Jayson, G. C., 3135
 Jenkins, J., 1953
 Jenkins, R. B., 920
 Jennings, T. A., 2811
 Jepson, C., 2055
 Joab, I., 2414
 Johansson, H., 134
 Johnson, E. H., 1607
 Johnson, K. A., 2726
 Johnson, M. M., 25
 Johnson, P. C., 3010
 Johnson, P. J., 25
 Jones, R. M., 2436
 Jones, R. R., 1801
 Jönsson, P.-E., 2749
 Joseph, G., 1959
 Joseph, R. R., 2692
 Joshi, M. G., 1289
 Jouffre, C., 599
 Jouffre, V., 2781
 Jung, S.-H., 1733
 Juvekar, R. R., 2425

K

Kaboo, R., 1904
 Kabuto, T., 1855
 Kaiser, J. S., 900
 Kakegawa, T., 1863
 Kaklamanis, L., 1021
 Kaleya, R., 1706
 Kamby, C., 123
 Kameyama, M., 1855
 Kane, R. A., 1615, 3146
 Kaneko, M., 972, 2251
 Kang, S., 2935
 Kanma, K., 2239
 Kao, G. D., 965
 Kaplan, A. M., 1827
 Kaplan, W. D., 1887
 Kaps, E. C., 2188
 Karakousis, C. P., 1270
 Karnell, L. H., 782
 Kasumi, F., 2281
 Katagiri, T., 2281
 Kato, Y., 2234
 Katsetos, C. D., 3190
 Katz, J., 1953
 Katz, J. A., 189
 Katzmann, J. A., 920, 1752
 Kaufmann, M., 1398
 Kavadi, V. S., 670
 Kawai, J., 3023
 Kawai, T., 2468
 Kawakami, Y., 46, 2245
 Keefe, D., 2757
 Keegan, G. T., 1899
 Keles, G. E., 1784
 Kelleher, D. P., 2374
 Keller, A., 2949
 Kelly, A., 1318
 Kelsen, D., 958, 2757
 Kelsen, D. P., 2224
 Kemeny, N., 958, 2757
 Kenemans, P., 1398, 2314
 Kennedy, J., 2935
 Kenter, G. G., 2307
 Kerr, C., 2352
 Keyes, J. W., Jr., 1355
 Khalid, H., 679
 Khan, A. S., 3190
 Khan, F., 2642
 Khanuja, P. S., 1217
 Khelfaoui, F., 722
 Kher, U., 697
 Kiechle-Schwarz, M., 2509
 Kies, M. S., 3159
 Kikuchi, M., 66
 Kilpatrick, M. G., 52
 Kilpatrick, S. E., 3227
 Kim, S., 664
 Kim, Y.-I., 893

Kimmel, D. W., 920
 Kino, I., 3089
 Kinzie, J. L., 1217
 Kirby, T. J., 1680
 Kirmani, S., 664
 Kish, J. A., 916
 Kitamoto, T., 3176
 Kitamra, T., 826
 Kitaoka, M., 592
 Kizaki, M., 1939
 Klein, A., 164, 2924
 Knapstein, P. G., 648
 Knip, M., 618
 Kobayashi, K., 168
 Kobayashi, M., 1821
 Koga, H., 2430
 Kohorn, E. I., 1323
 Koida, I., 2918
 Koka, A., 1680
 Kolodziejczyk, P., 2896
 Kommoss, F., 2509
 Konaga, E., 3097
 Konda, S., 61
 Konishi, I., 2321
 Kono, S., 2468
 Koopman, C., 2570
 Kopans, D. B., 311, 1196, 1212
 Kormanik, P., 1342
 Kornblith, A. B., 907
 Kornguth, P. J., 2944
 Korse, C. M., 2307
 Korzeniowski, S., 1591
 Koss, M. N., 2251
 Kovacs, C. S., 928
 Kovacs, K., 928
 Koyama, H., 872, 1595
 Koziol, J. A., 3063
 Kozwicz, D. L., 1367
 Kramer, B. S., 2726
 Kramer, L. C., 1367
 Krance, R., 1953
 Kraus, D. H., 697
 Kraut, M. J., 1217
 Kreienberg, R., 1398
 Krishna, L., 3190
 Kristen, P., 1398
 Kroog, G., 2808
 Krook, J. E., 1733, 2956
 Kruit, W. H., 2850
 Kubo, R., 592
 Kucik, N. A., 453
 Kuhl, D., 1607
 Kumada, H., 2918
 Kumamoto, M., 3023
 Kumar, N. B., 632
 Kun, L. E., 733, 2593
 Kunieda, K., 817
 Kuo, H.-C., 2497
 Kurachi, H., 2984

Kuross, S. A., 1733
 Kurtz, J. C., 2071
 Kurtz, M. E., 2071
 Kürzl, R., 2502
 Kushida, H., 1063
 Kusumoto, Y., 2234
 Kut, M., 1965
 Kuwano, H., 586, 2889
 Kuwano, M., 1230
 Kuzel, T. M., 3159
 Kwong, Y. L., 174

L

Laatikainen, T. J., 618
 Labianca, R., 2873
 Lacau-Saint-Guilly, J., 1933
 Laccourreye, H., 2781
 Laccourreye, O., 2781
 Lach, B., 1915
 Ladazack, J., 2979
 Lagrange, J.-L., 2352
 Lahti, E. I., 618
 Lai, K.-H., 2449
 Lampe, B., 2502
 Lanciano, R. M., 2979
 Land, C. E., 805
 Lane, J. M., 842
 Lange, B., 965
 Langholm, R., 933
 Lansac, J., 1283
 Lantos, J., 2653
 Laporte, J. P., 2930
 Lappi, D. A., 848
 Larsson, R., 2857
 Lasset, C., 2352
 Laszlo, J., 1509
 Latteri, M. A., 1945
 Lattin, P. B., 1217
 Lau, W. H., 2414
 Lauer, S. J., 197
 Laugier, A., 1933
 Launay, E., 3042
 Laurent, J.-L., 599
 Laut, V. M., 1792
 Lauweryns, J. M., 3164
 Laver, J., 1953
 Lavergne, A., 3042
 Lawrence, W., Jr., 2605
 Leake, B., 625
 Leatham, A., 3104
 Lebeau, B., 38
 Lebwohl, D. E., 74
 Le Cesne, A., 2791
 Le Chevalier, T., 2791
 Leclercq, M., 1533
 Ledger, G. A., 2589
 Lee, A. K. C., 1289
 Lee, C.-N., 2361
 Lee, F., 1615, 3146

Lee, I.-M., 1837
 Lee, J. J., 2908
 Lee, M. S., 152
 Lee, Y., 3034
 Leek, R., 1021
 Le Floch, O., 1283
 LeGatt, D. F., 3204
 Legha, S. S., 2476
 Lehne, G., 933
 Leimert, J. T., 916
 Leitch, J. M., 945
 Lejeune, S., 1021
 Lekas, M., 1927
 LeMaistre, C. A., 1513
 Lemarie, E., 38
 Lenel, J. C., 1621
 Leone, L., 1927
 Leong, S. P. L., 2268
 Leopold, K., 1243
 Lerma, E., 1778
 Levavi, H., 774
 Levin, B., 2885
 Levine, A. J., 640
 Levine, D. S., 1225
 Levison, D. A., 789
 Levitt, S. H., 1840, 2154, 2642
 Levy, J. F., 453
 Lewin, K. J., 1686
 Leytin, V., 164, 2924
 Li, B., 1686
 Li, D.-F., 66
 Li, J.-L., 3089
 Li, J.-Y., 1686
 Li, X.-R., 3089
 Liang, R. H. S., 174
 Lieberman, D., 2023
 Liebsch, N. J., 2261
 Lilleby, K., 715
 Linassier, C., 2930
 Lind, M., 1607
 Lindnér, P., 2749
 Lindtner, J., 1139
 Lininger, R. A., 1111
 Linke, K. A., 1265
 Lippman, S. M., 2719
 Lipton, A., 2949
 Lishner, M., 2924
 Littrup, P. J., 1615, 2016, 3146
 Liu, E. T., 1111
 Liu, F.-S., 1686
 Liver Cancer Study Group of Japan,
 The, 2772
 Livingston, R. B., 1177
 Livingstone, A. S., 1869
 Ljung, B.-M., 1000
 Lloyd, J., 2067
 Lo, J. Y., 2944
 Lockett, M. A., 466
 Lockwood, S. A., 565

Loizidou, M., 3104
 Long, H. J., 1733
 Long, S., 2101
 Longcope, C., 1125
 Longin, K., 715
 Longnecker, M. P., 1101
 Lookner, D. H., 3002
 Lopes, A., 90, 2491
 Loprinzi, C. L., 945, 1733
 Loseth, D. B., 907
 Louis, D. N., 1383
 Love, N., 2024
 Love, R. R., 1418
 Love, S. M., 2804
 Loven, D., 774
 Lu, J.-P., 573
 Lucas, R. J., 640
 Luckey, D. W., 203
 Lukens, J. N., 2710
 Luna, M. A., 152
 Lund, G. O., 2541
 Lurdell, G., 1348
 Luporini, G., 2873
 Luxen, A., 2836
 Lynch, H. T., 1184
 Lynch, J., 1184
 Lyster, M. T., 3159

M

MacDonald, R. N., 3204
 MacEachern, T. J., 3204
 Macerata, R. S., 2949
 MacFarlane, M. P., 3212
 Machidera, N., 592
 Mack, T. M., 1474
 Mackarem, G., 1289
 Madlensky, L., 2341
 Maeda, S., 1720
 Maehara, Y., 1230
 Maekawa, S., 586
 Mahmoud, H., 1953
 Mahoney, M. C., 1270
 Maihle, N. J., 2956
 Mailliard, J. A., 1733
 Maiorino, A., 1874
 Maire, J.-P., 2352
 Malin, M., 2118
 Man, Y. O. C. T. K., 2352
 Mancuso, A. A., 1193
 Mannami, T., 3097
 Manor, Y., 164
 Mansour, E. G., 381, 2672
 Marchant, D. J., 512, 0878
 Marcial, V. A., 450
 Marcove, R. C., 1253
 Marini, G., 1139
 Markoe, A., 1869
 Marks, L. B., 2964
 Marnett, L. J., 2885
 Marsden, H. B., 2579
 Marshall, T., 83
 Marshburn, J., 2366
 Martin, A., 1959
 Martin, A. A., 115
 Martin, L., 2828
 Martin, P. L., 3227
 Martineau, D., 848
 Martinelli, D. J., 1706
 Martinez, A., 640
 Masé, R. M., 928
 Mashimo, M., 3108
 Mason, J. B., 893
 Masuda, Y., 1939
 Masuzawa, H., 2321
 Matsuda, T., 592
 Matsuki, M., 2745
 Matsumoto, T., 12
 Matsumura, K., 1000
 Matter, R. A., 640
 Matthews, J. L., 1725
 Matías-Guiu, X., 1778
 Maubon, I., 599
 Mauceri, K., 440
 Mauch, P., 708
 Maurer, H. M., 2579
 May, E., 864
 Maygarden, S. J., 2996
 May-Levin, F., 864
 Mayne, S. T., 1556
 Mayzel, K., 1746
 McCarthy Lepore, J., 907
 McCarty, M. J., 3051
 McClay, E. F., 664
 McClay, M. E., 664
 McClintock, J., 1899
 McCormick, B., 430
 McCoy, C. B., 2024
 McDermott, E., 2276
 McDonald, G. S., 2374
 McEwan, J., 3190
 McGinnis, L. S., 2147
 McKean-Matthews, M., 3063
 McKenna, R. J., Sr., 221, 0244, 0536,
 2107
 McNeely, L. K., 740
 McQuirt, F., 1355
 McRae, R., 1927
 McRoberts, J. W., 2533
 Meagher, D. P., Jr., 740
 Medeiros, J., 1959
 Meisenberg, B., 1360
 Meister, B., 142
 Melchiorri, C., 1713
 Melioli, G., 2300
 Meloni, A. M., 2268
 Menard, O., 2460
 Menck, H. R., 1974, 2386
 Merajver, S. D., 1013

- Messina, C., 2562
 Mettlin, C., 228, 1615
 Mettlin, C. J., 1640, 3146
 Metz, R., 3080
 Meyer, J. S., 2287
 Meyer, W. H., 2593
 Mibu, R., 12
 Michelassi, F., 2908
 Michikawa, N., 1939
 Michon, J., 722
 Mick, R., 1965
 Mielicki, W. P., 1367
 Mignot, P., 2460
 Mikol, J., 686
 Milani, A., 2562
 Miller, A. A., 2949
 Miller, B., 3142
 Miller, D. C., 1383
 Miller, G. J., 3002
 Mills, G., 93
 Milner, P. G., 1584
 Milpied, N., 2930
 Minu, A. R., 578
 Mirro, J., 1953
 Missitzis, I., 1275
 Mistry, R. C., 2425
 Mitchell, D. W., 3023
 Mitsui, K., 3113
 Mitze, M., 648
 Miyake, A., 2984
 Miyamoto, C., 3190
 Mizutani, Y., 2546
 Möbus, V., 1398
 Moertel, C. L., 3034
 Mohler, J. L., 2996
 Moksness, J., 1817
 Monaghan, J. M., 90, 2491
 Mondrus, G. T., 1474
 Monnet, I., 2460
 Montie, J. E., 1
 Moore, J. O., 159
 Moore, T. D., 1164
 Mor, V., 2118
 Moran, C. A., 2251
 Moredo, T. F., 74
 Morgan, P. R., 789
 Morgenstern, G., 3135
 Mori, I., 2234
 Mori, M., 586, 3108
 Mori, S., 795, 1294
 Morishige, K., 2984
 Morita, M., 2889
 Moriya, T., 2972
 Mornet, M., 38
 Morodomi, T., 1863
 Morrill-LaBrode, A., 1125
 Morrow, G. R., 1409, 2676
 Morse, M., 3034
 Mortenson, L. E., 2204
 Mortimer, J. E., 453
 Mosseri, V., 722
 Mossman, J., 1160
 Mostofi, F. K., 1615
 Motomura, K., 872, 1595
 Mott, M. G., 3240
 Moulignier, A., 686
 Mounce, K., 2593
 Mourad, W. A., 1739
 Mouriessse, H., 864
 Mudad, R., 1360
 Mufarrij, A., 1699
 Mugishima, H., 972
 Mukherji, S. K., 1193
 Müller, M., 2307
 Müller-Hermelink, H. K., 1525
 Munck, J.-N., 810
 Mund, D. F., 2804
 Munson, J. L., 1289
 Munzenrider, J. E., 2261
 Murai, H., 2745
 Murakami, S., 2745
 Murata, M., 1939
 Murphy, B., 2757
 Murphy, G., 1640
 Murphy, G. P., 1615, 3146
 Murphy, W. M., 115
 Murraciale, X., 2352
 Muscat, J. E., 1847
 Musetta, G., 1874
 Muss, H. B., 2165
 Mutch, D. G., 1891
 Muto, M. G., 1309, 1318
 Muto, T., 4
 N
 Nagataki, S., 2234
 Nagura, H., 795
 Nakagawa, K., 1720
 Nakagawa, T., 817
 Nakaizumi, A., 826
 Nakajima, I., 2245
 Nakamine, H., 3023
 Nakamori, S., 1595, 1855
 Nakamura, R. M., 1655
 Nakamura, S., 2896
 Nakamura, T., 805
 Nakamura, Y., 2281
 Nakashima, T., 3108
 Nakata, K., 2234
 Nakayama, K., 2321
 Nanasawa, H., 61
 Naqao, M., 1063
 Naredi, P., 2749
 Narod, S. A., 2341
 Nassar, V. H., 1699
 Nayfield, S. G., 2726
 Neefe, J. R., 916
 Negami, T., 61
 Nelimark, R. A., 1733
 Nelson, D. F., 2828
 Nemeth, J., 3042
 Nemunaitis, J. J., 1725
 Neuenschwander, S., 722
 Nevo, Z., 949
 Newton, W. A., 2579
 Ng, I. O. L., 30
 Ng, M. M. T., 30
 Ng, W. G., 1309
 Ngan, R. K. C., 2414
 Nguyen, G.-K., 928
 Nguyen, H. N., 545
 Nicoll, J. A. R., 3240
 Nieberg, R. K., 1686
 Nieder, M., 3034
 Nigri, P. T., 1927
 Nikaido, T., 2321
 Nikiforov, Y., 748
 Ninfo, V., 2579
 Nirenberg, A., 940
 Nishikawa, T., 1634
 Nishimaki, T., 4
 Nishioka, S., 3023
 Nishiya, M., 3002
 Nixon, D. W., 2683
 Noda, S., 376
 Noguchi, S., 872, 1595
 Nome, O., 933
 Nour, M. A., 893
 Noventa, F., 2442
 Nussbaum, E., 2460
 Nygren, P., 2857
 Nzeako, U. C., 2765
 O
 Oakhill, A., 3240
 O'Briain, S., 1693
 O'Brien, J. P., 2757
 O'Brien, S., 1965
 O'Brien, S. M., 168
 O'Byrne, K. J., 2374
 Ochiai, M., 1063
 Ochs, J., 197
 O'Connell, J. X., 2261
 Odell, E. W., 789
 Odom, L. F., 203, 0740
 O'Fallon, J. R., 920, 0945
 Ogata, K., 66
 Ogata, T., 2468, 3113
 Ogata, Y., 1863
 Ogawa, I., 3113
 Ogihara, Y., 2798
 Ogura, S., 46, 2245
 Ohara, T., 3097
 Ohigashi, H., 826
 O'Higgins, N., 2276
 Ohira, M., 972
 Ohno, S., 2889

Ohno, T., 2555
 Ohori, M., 104
 Ohta, M., 61, 3176
 Ohuchi, N., 1294
 Okabe, I., 972
 Okamoto, K., 1634
 Okamoto, S., 1939
 Okamura, S., 3097
 Okuda, K., 61
 Okuda, S., 826
 Okuni, M., 972
 Okuyama, T., 1230
 Oliva, E., 1778
 Olsson, C. A., 1667
 Omagari, K., 2234
 O'Marcaigh, A. S., 2589
 Omura, M., 1634
 Onda, K., 1921
 Onizuka, M., 3113
 Onuma, N., 972
 Orita, K., 3097
 Orleans, C. T., 2051, 2055
 Orozco, R. E., 115
 Osborne, B., 159
 Osborne, B. M., 3083
 Osborne, C. K., 1135
 O'Shaughnessy, J., 2808
 Osteen, R. T., 366
 Osuch, J. R., 263, 0271
 Otal, T. M., 1237
 Owen, J. B., 2174, 3198
 Oya, M., 2896
 Ozisik, Y. Y., 2268
 Ozols, R. F., 2979
 Ozsahin, M., 1933

P

Paci, E., 3126
 Packer, R. J., 1827
 Pagano, J. S., 2397
 Pagnoni, M., 1713
 Paladini, D., 2491
 Palestro, G., 1568
 Pan, H.-B., 2449
 Pang, S., 1904
 Papa, G., 1792
 Papac, R. J., 2403
 Papadopoulos, N. E., 1265, 2476
 Papadopoulos, N. G., 1275
 Papamichail, M., 1275
 Parham, D. M., 2579
 Parker, S. H., 256
 Parnes, H. L., 1629
 Partin, A. W., 2996
 Pasquetti, W., 2300
 Patel, S. R., 1265
 Patil, P. K., 2425
 Paulson, E. K., 1360

Pearl, D. K., 3010
 Pearson, A. D. J., 3240
 Pearson, P., 3059
 Pecker, R., 2347
 Peier, A., 2268
 Peiper, S. C., 1959
 Perez, C. A., 453, 0466
 Perino, G., 2251
 Perlman, J. A., 2726
 Perry, J. J., 3051
 Persson, B. G., 2454
 Peters, W. P., 1360, 2964
 "Petites Cellules" Group, The, 38
 Petrek, J. A., 518, 0528
 Petrelli, N. J., 1270
 Pfisterer, J., 2509
 Pfeiderer, A., 2509
 Pharis, P., 1237
 Philpott, G., 466
 Philpott, G. W., 453
 Photopoulos, G., 3142
 Pialoux, G., 686
 Pich, A., 1568
 Pickering, R., 3104
 Pienta, K. J., 100
 Pierce, L. J., 477
 Pinkus, G., 708
 Pinto, A., 978
 Pinto, N., 2352
 Piscitelli, S. C., 834
 Piver, M. S., 656
 Plager, C., 1265, 2476
 Plank, G. S., 834
 Plaxe, S. C., 664
 Poe, D., 2593
 Polak, J. M., 134
 Polednak, A. P., 2863
 Pollack, A., 670, 2819
 Pollock, B. H., 197, 2647
 Poole, M. A., 740
 Poon, Y. F., 2414
 Poplin, E. A., 1217
 Porschen, R., 2218
 Portenoy, R. K., 907
 Post, K. D., 693
 Potchen, E. J., 263
 Prados, M. C., 1552
 Prat, J., 1778
 Pratt, C. B., 733, 2593
 Prestigiacomo, A. F., 1662
 Price, K. N., 1139
 Priest, J. R., 3034
 Pritchard, K. I., 1150
 Pritchard, M., 962
 Prosnitz, L. R., 159, 2964
 Province, M. A., 2287
 Pujol, P., 1601
 Punt, K. J., 2850
 Putterman, M., 722

Q

Quintana, E., 722
 Quintanilla-Martinez, L., 606

R

Raab, S. S., 1621
 Raben, M., 1355
 Raber, S. R., 834
 Radcliffe, J., 965
 Rader, J. S., 1891
 Radford, D. M., 1584
 Radnay, J., 164, 2924
 Raju, G. C., 1542
 Ramirez, L. H., 810
 Ramot, B., 3029
 Ramírez-Armengol, J. A., 1546
 Randall, M. E., 1303, 1355
 Rangnekar, V. M., 2533
 Ransom, D. T., 920
 Rao, B. N., 733
 Ratain, M. J., 168, 1965
 Ratcliffe, W. A., 83
 Ravdin, P. M., 381
 Ravid, M., 2924
 Raz, A., 1855
 Raziuddin, S., 2843
 Recht, A., 1746
 Redd, W. H., 1438, 1496
 Reddy, R., 1869
 Redman, B. G., 100
 Reed, E., 1612
 Reichardt, J. K. V., 1309
 Reid, B. J., 1225
 Reid, I. M., 1693
 Reilly, D., 2276
 Reiman, H. M., 2579
 Reintgen, D. S., 336
 Reister, T., 1335
 Relf, M., 1021
 Renard, L. G., 2261
 Renz, H., 2509
 Resch, N., 2055
 Rettig, W. J., 842
 Reynaud-Bougnoux, A., 1283
 Ribbert, H., 1525
 Ricard, M., 810
 Rice, T. W., 1680
 Richardson, J. L., 1474
 Richman, S. P., 1869
 Ries, L., 2101
 Ries, L. A., 1995
 Rifkin, M. D., 2811
 Riggs, M., 1607
 Rimer, B. K., 323, 1482, 2051, 2055
 Rinehart, M. E., 372
 Ring, S., 2476
 Rio, M.-C., 1045
 Rippstein, P., 1915
 Risch, H. A., 2341

- Roberson, N. L., 2034, 2687
 Robert, N. J., 878
 Roberts, C. S., 336
 Roberts, J. L., 693
 Robertson, G., 90
 Robinson, D., 949
 Roche, P. C., 2956
 Rodriguez, G. C., 93
 Rodriguez-Bigas, M. A., 1270
 Rodvold, K. A., 834
 Roetzheim, R. G., 625, 2028
 Rogers, B. B., 962
 Rohan, B., 2004
 Rokutanda, M., 2468
 Rollason, T., 83
 Roncadin, M., 978
 Roncalli, M., 134
 Rorke, L. B., 1827
 Rosen, B., 2341
 Rosen, V., 842
 Rosenberg, A. E., 2261
 Rosenberg, S. A., 3212
 Rosman, M., 1323
 Rosner, G. L., 2964
 Ross, B. C., 2436
 Ross, J. S., 2811
 Ross, M., 1360, 2476, 2964
 Rossi, R. L., 1289
 Rosso, R., 2300
 Rotman, M., 2828
 Rougier, P., 810
 Rouyer, N., 1045
 Rozenblit, A., 1706
 Rubenstein, L., 2190
 Ruckdeschel, J. C., 1458
 Rudenstam, C.-M., 1139
 Rudolph, R., 3063
 Ruijs, C. D. M., 703
 Rup, B., 842
 Rusch, V. W., 1225
 Rush, C., 466
 Rushing, D. A., 834
 Ruskone-Fourmestiaux, A., 3042
 Russell, G. B., 3227
 Rutqvist, L. E., 1156
 Ryder, W. D., 3135
- S**
- Sabido, O., 599
 Sachdanandam, P., 78
 Sachs, N., 2579
 Sadanaga, N., 586
 Safa, A. R., 2908
 Sagawa, M., 2239
 Saito, T., 2889
 Saito, Y., 2239
 Saitoh, S., 2918
 Sakamoto, G., 2281
 Sakurada, A., 2239
 Salgia, R., 1887
 Salmeron, M., 854
 Saltz, L., 958, 2224, 2757
 Sampson, S., 2004
 Sandberg, A. A., 2268
 Sanders, L. E., 1289
 Sands, S., 2570
 Sanuki, E., 972
 Sarbia, M., 2218
 Sarna, L., 2079
 Sartor, O., 1612
 Sasaki, Y., 1855
 Sasano, H., 795
 Sato, E., 805
 Sato, K., 3097
 Sato, M., 817, 2239
 Sato, T., 1634
 Satomi, A., 2745
 Sauerbrei, W., 2509
 Sauerwein, H. P., 2879
 Sausville, E. A., 3051
 Sawada, K., 61
 Sawada, M., 2984
 Sawyer, J. R., 767
 Sawyers, C., 1904
 Scardino, P. T., 104
 Schaid, D. J., 1752
 Schain, W. S., 2666
 Schapira, D. V., 632, 2366
 Schatzkin, A., 1101
 Scheithauer, B. W., 920, 3010
 Schiffer, C. A., 1629
 Schilsky, R. L., 168, 1965
 Schlienger, M., 1933
 Schlienger, P., 722
 Schmid, C., 878
 Schmidt, B., 2935
 Schmidt, D., 2579
 Schmidt-Rhode, P., 1398
 Schmidt-Ullrich, R., 878
 Schneider, A., 893
 Schnitt, S. J., 1746
 Schofield, J., 1801
 Schou, G., 123
 Schultheiss, T. E., 2174
 Schultz, D., 3118
 Schultz, D. J., 965
 Schumacher, U., 3104
 Schutter, E. M. J., 1398
 Schwade, J., 1869
 Schwartz, G., 958
 Schwartz, L. H., 1933
 Schwartz, M. R., 1519
 Schwartz, P. E., 1323
 Schwartzentruber, D. J., 3212
 Scimeca, J. A., 1050
 Scoppa, G., 1874
 Scott, B. A., 52
 Scott, C. B., 2828
 Seaman, J. J., 2949
 Sears, J. D., 1303
 Seematter, R. J., 854
 Seki, T., 817
 Selch, M. T., 1827
 Selhub, J., 893
 Semenzato, G., 2562
 Seng, S.-H., 2352
 Sengeløv, L., 123
 Senn, H.-J., 1139
 Setrakian, S., 1739
 Severin, M., 1184
 Shah, S., 93
 Shahab, I., 3083
 Shapira, J., 2924
 Shapiro, C., 2924
 Shapiro, H., 164
 Shapiro, S., 231
 Sharma, R. K., 1725
 Shea, M. C., 1342
 Shearer, P., 1953
 Sheikh, A., 2843
 Shen, Q., 3089
 Sherrieff, M., 789
 Sheth, D. S., 1253
 Shibuta, K., 3108
 Shibuya, M., 1921
 Shiff, J., 3029
 Shiga, C., 795
 Shiga, K., 795
 Shimada, H., 2579, 3223
 Shimizu, S., 61
 Shimosato, Y., 542
 Shinomiya, N., 2468
 Shirahama, H., 805
 Shirai, T., 1063
 Shiro, T., 817
 Shirouzu, K., 1863
 Shively, J. E., 1575
 Shpilberg, O., 3029
 Shumate, D. K., 3227
 Siegall, C. B., 1006
 Sienko, D. G., 263
 Silliman, C. C., 203
 Silver, B., 708, 1746
 Silverberg, S. G., 2972
 Simon, R., 2614
 Simonsen, E., 2329
 Simpson, J. F., 1575
 Sinicrope, F. A., 2908
 Slizofski, W. J., 3190
 Smart, C. R., 296, 0301
 Smith, D. S., 1516
 Smith, H., 1000
 Smith, T. J., 878
 Snyder, R., 1139
 Snyderwine, E. G., 1070
 Soares, R. L., Jr., 466
 Sober, A. J., 2935

Sobin, L. H., 2385
 Sohn, C., 1398
 Solomon, A. R., 2935
 Sondik, E. J., 995
 Southey, M. C., 2436
 Spachynski, K. A., 3204
 Spanier, S. S., 2268
 Speights, V. O., 1607
 Speights, V. O., Jr., 1899
 Spiegel, D., 1453, 2570
 Spiegelman, D. L., 1125
 Spitz, M., 2719
 Springall, D., 134
 Srivastava, G., 30
 Stafford, D. W., 1533
 Stamey, T. A., 1662
 Stanley, M. A., 884
 Stasi, R., 1792
 Stathopoulos, G. P., 1275
 Steele, G. D., Jr., 1979
 Steiger, Z., 1217
 Steinherz, P. G., 3234
 Stellman, S. D., 1847
 Stemmermann, G. N., 556
 Stewart, H., 1160
 Stine, K. C., 767
 Stommel, M., 2128
 Stoter, G., 2850
 Strain, J. D., 203
 Straumfjord, J. V., 2366
 Strong, E. W., 697
 Studnicki, J., 2366
 Su, J. Q., 2956
 Sugimachi, K., 586, 1230, 2889, 3108
 Sugimura, H., 3089
 Sugimura, T., 1063
 Suk, S., 1927
 Sukoh, N., 46, 2245
 Sullivan, D. C., 2944
 Sunagawa, M., 578
 Sung, C.-C., 3010
 Suster, S., 2251
 Suttie, J. W., 1533
 Sutton, L., 965
 Sutton, S. M., 2194
 Suzuki, M., 2468
 Suzuki, T., 4, 3108
 Swafford, J., 182
 Swanson, D. A., 2819
 Swanson, G. M., 1523
 Swedish Anaplastic Thyroid Cancer
 Group, The, 1348
 Synnestvedt, M., 3118

T

Tabery, R. L., 1752
 Tada, S., 12, 2430
 Tajima, H., 2234
 Takagi, K., 2468

Takahashi, S., 2239
 Takaoka, K., 842
 Takeda, K., 2798
 Takekawa, H., 46, 2245
 Takenaka, A., 826
 Takenaka, T., 3023
 Takeshita, I., 3176
 Tamai, S., 2468
 Tamaya, T., 2555
 Tanaka, M., 3089
 Tanaka, N., 3097
 Tanaka, O., 4
 Tanaka, S., 805
 Tanaka, Y., 1821
 Tanioka, H., 2234
 Tanosaki, R., 1939
 Tao, Y., 2224, 2757
 Tarone, R. E., 424
 Tasaka, K., 2984
 Tashiro, Y., 1634
 Tateishi, J., 3176
 Tatsuta, M., 826
 Tattersall, M., 1139
 Tavelin, B., 2520
 Taylor, I., 3104
 Taylor, M. E., 453, 0466, 1680
 Taylor, P. R., 1686
 Tefft, M., 1680
 Teh, M., 1542
 Tennvall, J., 1348
 Teot, L. A., 3227
 Testa, A., 1945
 Tewksbury, D. A., 834
 Thangaraju, M., 78
 Theodossiou, C., 2808
 Thibault, A., 1612
 Thiebaut, J.-B., 686
 Thiel, R. P., 1323
 Thirlwell, M., 1808
 Thomas, J. R., 767
 Thompson, C. J., 3118
 Thompson, H. J., 1050
 Thompson, W. D., 279
 Thorne, R. N., 3240
 Thun, M. J., 2885
 Thurel, C., 686
 Tibblin, S., 1348
 Tidebrant, G., 2749
 Tieder, M., 949
 Timmer, J. G., 2879
 Todd, D., 174
 Toi, A., 3146
 Tokunaga, M., 805
 Tolcher, A., 2808
 Tong, W., 2224, 2757
 Tonin, P., 2341
 Toogood, I., 3034
 Torres-Melero, J., 1546
 Touboul, E., 1933

Tran, K., 2139
 Tran, K. N., 74
 Tremolada, F., 2442
 Trentin, L., 2562
 Triche, T. J., 2579
 Trimble, E. L., 2208
 Trimbos, J. B., 2307
 Tripuraneni, P., 3063
 Trizna, Z., 2719
 Trovó, M. G., 978
 Trucco, G., 1739
 Tsang, S. W. Y., 30
 Tso, C.-L., 1904
 Tsokos, M., 2579
 Tsubota, A., 2918
 Tsuchida, Y., 972
 Tsuneyoshi, M., 2896
 Tucker, E., 3212
 Tura, S., 1792
 Tzeng, C.-C., 2497
 Tzeng, W.-S., 2449
 Tzy-Jun, Y., 2757

U

Ucar, A., 1869
 Uchida, H., 1939
 Uchiyama, S., 817
 Ueda, K., 1821
 Uehara, H., 826
 Uemura, Y., 805
 Ueo, H., 3108
 Ulbright, T. M., 1335
 Unger, E. R., 1699
 Ungerleider, R. S., 2208
 Urist, M. M., 782
 Ushijima, T., 1063
 Usuda, K., 2239
 Utsunomiya, T., 2896

V

Vaitkevicius, V. K., 1217
 Valagussa, P., 2483
 Valenza, R., 1945
 Valeri, P., 978
 Validire, P., 722
 Valles, B., 1309
 van Baarlen, J., 703
 van Bommel, P. F. J., 2314
 van der Lelie, H., 2879
 Vanderschueren, R., 2460
 Van de Voorde, W. M., 3164
 van Hoogenhuyze, D. C., 2850
 van Kempen-Hartevelt, M. L., 703
 Van Kirk, M. A., 1680
 Van Poppel, H. P., 3164
 van Unnik, A. J. M., 2579
 van Zaanen, H. C. T., 2879
 Vaquero, M., 1778
 Vara, E., 1546

Vaught, N. L., 945
 Veeder, M. H., 945
 Vender, J., 3190
 Venter, D. J., 2436
 Venturini, M., 2300
 Verbeken, E. K., 3164
 Veronesi, U., 1660
 Verstraeten, R. A., 1398
 Vetter, D., 16
 Veyret, C., 599
 Viale, G., 134
 Vicini, F. A., 640
 Vielh, P., 722
 Vijayalakshmi, T., 78
 Villamor, J., 1552
 Villar, H. V., 2386
 Vlamis, V., 907
 Vogel, R. L., 2483
 Vogelzang, N. J., 168, 1965
 Vokes, E. E., 168
 Vollmers, H. P., 1525
 von der Masse, H., 123
 von Eschenbach, A. C., 2819
 Vredenburg, J., 1360
 Vredenburg, J. J., 2964
 Vukelja, S. J., 3051

W

Wadler, S., 1706
 Wagner, J.-P., 2352
 Wahlberg, P., 1348
 Wakabayashi, K., 1063
 Wakabayashi, M., 817
 Waldman, F., 1000
 Walker, E. B., 1335
 Wallin, G., 1348
 Walsh, T. N., 1693
 Wang, D.-Y., 3089
 Wang, C.-Q., 1686
 Wang, L.-Q., 2454
 Wang, S.-T., 2497
 Wara, W. M., 1827
 Ward, B. A., 1556
 Warrell, R. P., Jr., 1882
 Watanabe, H., 1855
 Watanabe, M., 586, 2889
 Watanabe, N., 2245
 Watson, N. E., Jr., 1355
 Watterson, J., 3034
 Wazer, D. E., 878
 Weaver, C., 715
 Webber, B. L., 2579
 Weber, B. L., 1013
 Wee, A., 1542
 Weeks, D. A., 1817

Wei, D., 174
 Weinrich, S., 2079
 Weinstein, G., 2781
 Weir, D. G., 2374
 Weiss, A.-M., 16
 Weiss, M. A., 1882
 Weiss, R. B., 3051
 Welch, W. R., 1309
 Welsch, C. W., 1055
 Wender, D. B., 945
 Wenger, J.-J., 16
 Werner, D. C., 2366
 Westermann, R., 1398
 Wheeler, T. M., 104
 Whitaker, R. S., 93
 White, D. E., 3212
 White, J. R., 640
 White, R. L., Jr., 3212
 Wick, M. R., 1584
 Wickert, R. S., 3023
 Widmark, A., 2520
 Wiernik, P. H., 1706
 Wikström, L.-M., 142
 Wilander, E., 134
 Wilgus, L., 664
 Wilkins, E. W., Jr., 606
 Willers, R., 2218
 Willett, W. C., 1085
 Williams, D. W., III, 1355
 Williams, R., 25
 Williams, R. D., 2541
 Williams, S., 1891
 Willits, M.-j., 2172
 Wilson, C. B., 1921
 Wilson, H. L., 203
 Wimbish, K., 640
 Winer, E. P., 410
 Wingren, S., 2329
 Winick, N. J., 962
 Witzig, T. E., 1752, 2956
 Wold, L. E., 1752, 2956
 Wolf, C., 1045
 Wolf, M., 916
 Wolfe, W., 1243
 Wolff, P. A., 632
 Wolfson, P., 2804
 Woloschak, M., 693
 Wong, G., 907
 Wong, K. F., 174
 Wood, D. P., Jr., 2533
 Wood, W. C., 994, 1132, 2606
 Woods, M. N., 1125
 Wu, C.-C., 2361
 Wyatt, S. W., 565
 Wynder, E. L., 1847
 Wynstra, N. A., 491

X

Xian, M.-S., 573
 Xiang, Y.-Y., 3089
 Xu, H., 1309

Y

Yagoda, A., 774
 Yamamoto, N., 805
 Yamamoto, T., 3113
 Yamamura, K., 1720
 Yamazaki, K., 61, 2245
 Yanagawa, T., 2798
 Yancik, R., 1995, 2101
 Yang, C.-F., 2449
 Yano, H., 1821
 Yano, M., 2234
 Yao, B.-L., 2497
 Yao, T., 12, 2430, 2896
 Yao, T. J., 2224
 Yasuda, M., 2889
 Yasutomi, M., 592
 Yates, A. J., 3010
 Ying, W., 848
 Yip, T. T. C., 2414
 Yokoya, Y., 3023
 Yokoyama, T., 1821
 Yoshida, O., 2546
 Yoshikawa, H., 842
 Yost, R., 1243
 Yousem, D. M., 2828
 Yu, R. C., 1801
 Yu, Y., 1686
 Yuan, B., 1959
 Yun, A. J., 2944

Z

Zagars, G. K., 670, 2819
 Zagonel, V., 978
 Zaki, S. R., 1699
 Zalupski, M. M., 2268
 Zambello, R., 2562
 Zappa, M., 3126
 Zaverternik, J. J., 2024
 Zbieranski, N., 3227
 Zelenakas, K., 2949
 Zemer, R., 164
 Zhang, G. N., 1933
 Zhang, X.-Z., 2996
 Zhang, Z.-F., 1768
 Zhao, Z., 810
 Zheng, T., 1556
 Zimmerman, D., 2589
 Zimmerman, R. A., 1827
 Zinzani, P. L., 1792
 Zucker, J.-M., 722

